Search

Select A Team:

Funded Research

UCI Anti-Cancer Challenge

October 10, 2026

The UC Irvine Anti-Cancer Challenge advances the UCI Health Chao Family Comprehensive Cancer Center's research mission by funding pilot projects that help investigators generate crucial preliminary data for high impact research.

2025 Funded Research

2025 TRACK 1: PILOT PROJECTS 

Defining and Predicting Psychosocial Risk After Surgical Treatment and Reconstruction of Melanoma
I
nvestigator
Miles J. Pfaff, MD, Department of Plastic Surgery, UC Irvine School of Medicine
Cutaneous melanoma often requires surgery and reconstruction, which can affect patients’ appearance, recovery, and overall well-being. This study will follow patients over time to understand how treatment influences anxiety, stress, and quality of life and will identify factors that place some individuals at higher risk
for psychosocial challenges after surgery. The findings will help clinicians better counsel patients and develop targeted support strategies to improve recovery and patient-centered outcomes, particularly in Orange County, where melanoma incidence and mortality are higher among certain populations, including non-Hispanic White females, non-Hispanic White males, and Hispanic/Latino males. A patient stakeholder with lived experience of melanoma surgery will also participate in study design and interpretation of patient reported outcomes, strengthening the patient-centered relevance of the research and supporting future potential PCORI-focused patient engagement efforts.

Investigating the impact of PFAS exposure via drinking water on ovarian cancer outcomes
Investigator
Carolina Villanueva, MPH, PhD, Department of Environmental and Occupational Health, UC Irvine Joe C. Wen School of Population and Public Health
The respective pilot project will examine whether exposure to chemicals known as per and polyfluoroalkyl substances (PFAS) in drinking water are associated with ovarian cancer (OC) survival among women diagnosed in California and determine who may be more susceptible to their effects. PFAS are found widely in the environment and are present in nearly everyone’s blood. With increasing evidence of their negative health effects and recent reports that more than 200 million Americans are served by drinking water with detected PFAS levels, they present a serious public health concern. Considering the poor prognosis of OC, the extent of PFAS exposures, and drinking water regulations that are currently shifting, this study will provide much needed evidence of the potential impact of PFAS on OC survival, responsiveness to treatment, and possible contributions to disparities in outcomes.

A New Strategy to Kill Kinase Inhibitor Resistant Tumors
Investigator
Anand Ganesan, MD, Department of Dermatology, UC Irvine School of Medicine
Small molecule inhibitors that target kinase mutations observed in cancer can rapidly shrink tumors with the relevant mutations, but these tumors can recur rapidly (< 6 months) by activating signaling loops that bypass the effects of kinase inhibitors. Kinase inhibitor resistant tumors are no longer responsive to either kinase inhibitor therapies or immunotherapies, and new approaches are needed to prevent resistance/ treat resistant tumors. UCI-developed drugs that target CDC42 signaling can block signaling loops activated in resistant tumors, identifying a new way to treat kinase inhibitor resistant tumors. We uncover how CDC42 inhibitors developed by our group kill kinase inhibitor resistant tumors and identify CDC42 signaling pathways that are amplified in kinase inhibitor resistant human tumors.

Reducing Avoidable Emergency Department Use Among Cancer Patients in Safety-Net Hospitals
Investigator
Annie Ro, PhD,
Department of Health, UC Irvine Joe C. Wen School of Population & Public Health
Many cancer patients visit the emergency room for issues that could be better handled in a regular doctor's office. Regular use of the emergency room can lead to higher costs for hospital systems and worse outcomes for these patients. Our project uses local health data from Los Angeles County to understand why this happens, focusing on how factors like housing, language, and insurance status raise a cancer patient's risk to use the ED when they don’t have to. We plan to develop a predictive tool to help clinicians identify high-risk patients early so they can provide extra support and navigation services. This work aims to make cancer treatment more efficient, especially for patients who get their medical care in the safety-net system.

Q-CODE: Quality of Life with Combined Estrogen Patch and Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer
Investigator
Arash Rezazadeh, MD,
Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Current treatments for advanced prostate cancer are effective but often cause significant side effects that reduce patients’ energy, physical strength, and overall quality of life. This study tests a new approach that uses an estrogen patch instead of standard hormone therapy, combined with a well-tolerated medication (darolutamide), to treat the cancer while reducing these side effects. By preserving important hormones in the body, this strategy may help patients maintain their daily functioning and feel better during treatment. If successful, this research could lead to safer, more patient-centered treatments and support larger future clinical trials.
 
Synergistic Immunomodulation in Pancreatic Ductal Adenocarcinoma using cDC1 Vaccines, COX-2 Inhibition, and CIML NK Cells
Investigator
Aydin Eresen, PhD,
Department of Radiological Sciences, UC Irvine School of Medicine
Pancreatic cancer is exceptionally difficult to treat because the tumor creates a protective “shield” that prevents the body’s immune system from attacking it. This project tests a new combination therapy designed to break down that shield using an anti-inflammatory drug, while simultaneously training the immune system with a specialized vaccine and enhanced immune cells to find and destroy the tumor. By also using advanced MRI scans to monitor the treatment's success without needing invasive biopsies, this pilot study will provide the essential data needed to secure federal funding for larger studies, ultimately paving the way for new clinical trials for pancreatic cancer patients.

Developing a Functional Immune-oncology Platform for Pancreatic Ductal Adenocarcinoma
Investigators
Christopher Halbrook
, PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
Lisa Wagar, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Pancreatic cancer is one of the deadliest cancers and is especially difficult to treat because the immune system cannot effectively attack the tumor. This project develops a new laboratory model using patient tumor and immune tissues to better understand how pancreatic cancer suppresses immune responses. By testing immunotherapies and nanoparticle-based treatments in this system, the research aims to identify strategies that could make treatments more effective. Ultimately, this work could help guide the development of new therapies to improve survival for patients with pancreatic cancer.

Evaluating tumor microenvironment-mediated radioprotection and FLASH radiotherapy in an in-vitro vascularized model of cervical cancer
Investigator
Christopher C.W. Hughes,
PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
Cervical cancer remains a significant cause of cancer-related deaths in women worldwide, and while radiotherapy is a cornerstone of treatment, the tumor microenvironment - including factors like poor oxygenation and complex cellular interactions - can actively shield cancer cells from radiation, limiting treatment effectiveness. Standard 2D cell culture models often fail to capture these protective features, making it difficult to predict how new treatment strategies will perform in patients. Our research utilizes an innovative “organ-on-a-chip” technology to create a miniature, human cell-based vascularized 3D model of cervical cancer that closely mimics the complex tumor environment in the human body, allowing us to study how the tumor microenvironment influences radiation response. Using this advanced platform, we will investigate whether FLASH radiotherapy - an emerging technique that delivers radiation at ultra-high dose rates - can overcome these microenvironmental barriers while also sparing surrounding healthy tissue; potentially offering a safer and more effective alternative to conventional radiotherapy for patients with cervical cancer.
 
Development of an Intelligent Chatbot to Aid Quit-Smoking Support Groups
Investigator
Connie (Cornelia) Pechmann
, PhD, MBA, MS, UC Irvine Paul Merage School of Business
This research aims to enhance the performance of a chatbot to assist individuals in small, private, online, peer- support groups for quitting smoking, addressing the challenge of providing rapid responses when human members are unavailable. The chatbot, driven by Artificial Intelligence (AI), identifies the common post types or topics discussed in the support groups and generates a variety of engaging responses. This project aims to enhance the accuracy, relevance, and safety of chatbot-generated responses through retrieval-augmented generation (RAG) to select the most relevant candidate responses, the testing of multiple strategies to optimize the final responses, and the detection and minimization of hallucination responses by cross-referencing with authoritative medical sources. Improved chatbot responses will increase engagement in the support groups, both peer-to-chatbot and peer-to-peer, thus improving quit rates, with significant implications for public health

Expanding the Degradome of Bypassing E-Ligase Targeting Chimera (ByeTACs)
Investigator
Darci J. Trader
, PhD, Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy and Pharmaceutical Sciences
ByeTACs (Bypassing E3-Ligase Targeting Chimeras) are a new type of drug design that helps cells remove harmful proteins. Instead of relying on the established protein tagging system, ByeTAC molecules bring a disease-causing protein directly to the cell’s degradation machinery, called the proteasome, so it can be broken down and removed. This strategy can bypass biological steps that limit many current protein-degrading drugs and may allow for targeting proteins that were previously difficult to eliminate. By directly guiding unwanted proteins to destruction, ByeTACs could open new possibilities for treating diseases such as cancer, neurological disorders, as well as infectious diseases.

Leveraging Telomere Biology in Pathobiology and Treatment of Myeloproliferative Neoplasms
Investigator
Feng Qiao,
PhD, Department of Biological Chemistry, UC Irvine School of Medicine
Myeloproliferative neoplasms (MPNs) are common blood cancers in which abnormal blood cells overgrow due to genetic mutations that can arise decades before patients are diagnosed, yet it remains unclear why some people develop aggressive disease while others do not. This project investigates whether the length of telomeres — the protective caps on the ends of chromosomes that shorten as cells divide and age — plays a key role in determining which blood cancer-driving mutations survive and expand over a lifetime, by using advanced DNA sequencing to identify genetic variants in telomere-regulating genes across MPN patients of different ages. If successful, this research could lead to a simple blood test that measures telomere biology at diagnosis to guide doctors in choosing the most effective therapy for each individual patient, moving MPN treatment from a one-size-fits-all approach toward personalized, precision medicine.

The role of natural immunity in modulating antitumor T cell responses
Investigator
Francesco Marangoni
, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Elevated hygiene levels in highly developed countries may increase the incidence of tumors. In this Anti-Cancer Challenge proposal, we will use mouse models bearing a variety of natural microbes at all barrier surfaces to study the mechanisms linking the continuous exposure to microorganisms and protection from melanoma, which is a highly prevalent cancer in our catchment area. Our research will pave the way to medical interventions or public health strategies to decrease tumor incidence in highly developed nations.

LIFT: Lifestyle Improvement to Facilitate Tumor-immunity
Investigator
Gary Deng, MD, PhD,
Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Immunotherapy can eliminate all detectable cancer before surgery in patients with melanoma or bladder cancer, but this occurs in fewer than half of patients and the reasons are not well understood. The LIFT study will investigate whether a patient’s everyday behaviors—physical activity, sleep, stress, and diet— influence how well a patient’s immune system responds to immunotherapy, using a fitness tracker and smartphone app to monitor these behaviors throughout treatment while tumor tissue and blood are analyzed before and after therapy. If specific lifestyle factors emerge as meaningful predictors, this research will pinpoint the intervention targets for a larger clinical trial testing whether helping patients adopt healthier lifestyle habits during treatment can improve cancer outcomes.

ACCESS-LCS: Adjunctive Cheek Cell Evaluation Using Spectroscopy to Enhance Risk Stratification in Lung Cancer Screening
Investigator
Gelareh Sadigh
, MD, Department of Radiological Sciences, UC Irvine School of Medicine
Adherence to lung cancer screening with low dose computed tomography remains low with multiple contributing patient-, provider-, and system-level barriers. Our study will assess the feasibility and acceptability of check swab-based test for lung cancer screening and patients’ and providers’ preferences for this test compared to low dose computed tomography. We will further explore agreement rate between the two tests as well as cancer rate and follow-up test utilization among patients with discordant test results. Because cheek swab collection is simple, and easily integrated into routine primary care workflows, it may also reduce structural barriers and expand access to screening, particularly in underserved populations.
 
Targeting the RNA Exosome to Induce Immunogenic RNA Stress and Enhance Cancer Immunotherapy
Investigator
Ivan Marazzi, PhD
, Department of Biological Chemistry, UC Irvine School of Medicine
The RNA exosome is a cellular system that removes faulty or excess RNA to maintain cell health. When this system is disrupted, abnormal RNA accumulates and can trigger immune responses that help the body recognize cancer cells. This project will investigate whether blocking the RNA exosome can enhance these immune signals and improve responses to immunotherapy. This approach may offer a new treatment strategy for cancers that currently do not respond well to existing therapies, such as lung cancer, melanoma, and triple- negative breast cancer.

Human ILC2s Orchestrate Antitumor Immunity via Cytotoxicity and Nonconventional Antigen Presentation to CD8 T Cells
Investigator
Jianhua Yu,
PhD, Department of Medicine, UC Irvine School of Medicine
We study a special type of immune cell in the human body called ILC2s and recently found that these cells can directly kill tumor cells. The current project aims to understand how ILC2s work specifically with “killer” T cells to recognize and destroy cancer cells. Our research focuses on how ILC2s communicate with and activate killer
T cells, helping them persist longer and respond more effectively to tumors. By understanding how ILC2s and killer T cells work together, this research may lead to new ways to treat cancer and strengthen the body’s natural ability to fight it.
 
The role of donor sleep on allo-HSCT immune reconstitution and outcomes.
Investigator
Katharine Simon, PhD, Department of Pediatrics, UC Irvine School of Medicine
Stem cell transplantation is a life-saving treatment for a broad spectrum of malignant and non-malignant blood conditions, but the success of treatment depends heavily on the quality of the stem cells. This study examines whether donor’s sleep in the weeks prior to donation affects how well the stem cells work. By tracking sleep with wearable devices, we aim to identify sleep as a simple, low-risk way to improve transplant outcomes. Given that sleep is readily modifiable, our findings have the potential to inform practical recommendations that improve increase stem cell quality and increase the likelihood of successful stem cell transplantation.

Methionine Restriction and the Epitranscriptome in Cancer
Investigator
Klemens Hertel,
PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
Cancer cells have a unique weakness: they depend heavily on the amino acid methionine to grow and divide, while healthy cells can manage without it by using a similar building block called homocysteine. This pilot project will use cutting-edge technology to examine how reducing methionine changes small chemical methylation marks that are added to RNA molecules in the cell. These marks help control how RNA is processed and used to make proteins, and our work aims to show if low methionine disrupts these marks in ways that interfere with normal RNA handling, ultimately slowing cancer growth. By revealing these molecular links, the research could pave the way for new therapies combining dietary restrictions with targeted drugs, improving cancer treatment outcomes and reducing side effects for patients.

Depression Phenotype and Organ-Specific Aging in Cancer Caregivers
Investigator
Michael A. Hoyt
, PhD, Department of Global Health and Biobehavioral Sciences, UC Irvine Joe C. Wen School of Population & Public Health
Family members who care for loved ones with cancer often experience chronic stress, sleep loss, and emotional exhaustion that can quietly take a toll on their own health. This study examines whether these caregiving demands speed up biological aging in specific organs—such as the heart, brain, and immune system—using advanced blood-based markers. By linking changes in mood, fatigue, and sleep to measurable changes in the body, this research will help explain how caregiving stress “gets under the skin.” Findings will inform future interventions designed to protect the long-term health and well-being of the millions of family caregivers who are essential to cancer care.
 
Epithelioid models for cell competition
Investigator
Nicholas Baker, PhD,
Department of Developmental & Cell Biology, UC Irvine Charlie Dunlop School of Biological Sciences
This is a project to evaluate the possibility that tissues have an intrinsic defense mechanism against cancer called cell competition, and develop a method for studying it using mouse esophageal cells. Cell competition would eliminate potential cancer cells by recognizing large chromosome differences from normal cells. This could be part of the body’s defense against many cancers including common cancers such as breast and colon. An experimental model for cell competition developed using mouse cells will enable studies aiming to enhance cell competition in cancer prevention, and obtain better understanding of how cell competition sometimes fails and allows cancers to develop.

Exploring Diet-Drug Synergy to Potentiate PRMT5 Inhibitors in Glioblastoma
Investigator
Peter Kaiser
, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
This project will explore whether specific dietary changes can improve the effectiveness of new drugs that target PRMT5, a protein important for the growth of glioblastoma, an aggressive brain cancer. By testing these strategies in human glioblastoma cells and intracranial xenograft mouse models, the work will
determine whether diet can safely make cancer cells more vulnerable to treatment. The findings could identify simple, nutrition-based approaches that enhance current therapies without adding significant toxicity. Ultimately, this research aims to lay the groundwork for more effective, personalized treatment strategies that improve outcomes for patients with glioblastoma.
 
Epigenetic Reprogramming of iPSC-derived CAR T Cells to Enhance Functional Persistence
Investigator
Ran Jing
, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
CAR T cell therapy is a powerful cancer treatment, but it is currently limited by cost, manufacturing time, and the need for patient-specific cells. Our research aims to develop a more accessible “off-the-shelf” therapy by using stem cells to generate immune cells in the lab. We are identifying small molecules that help these cells stay active, grow well, and resist exhaustion when fighting cancer. This work has the potential to make life- saving immunotherapies more effective, scalable, and available to a broader range of patients.

Combinatorial targeting of ferroptosis in TNBC: A pilot study in vitro
Investigator
Richard Van Etten
, MD, PhD,  Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Triple-negative breast cancer (TNBC) is CFCCC catchment area priority cancer whose current therapy is inadequate. TNBC has been shown to be uniquely sensitive to agents that induce a process known as ferroptosis, where iron in the cell triggers membrane damage and cell death. This research will explore whether combinations of existing drugs that enhance ferroptosis could work together, increasing the anti-cancer effect while minimizing toxicity. The results of the research could trigger further studies aimed at developing new therapeutic approaches targeting ferroptosis for TNBC and other hard-to-treat solid tumors including pancreatic adenocarcinoma and glioblastoma.

Reinvigorating melanoma anti-tumor immunity by inhibiting PSGL-1 immune checkpoints on myeloid cells
Investigator
Roberto Tinoco,
PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
This research focuses on a specific molecule called P-selectin glycoprotein ligand-1 (PSGL-1), found on myeloid cells. We believe PSGL-1 may play a significant role in dampening immune responses against melanoma, allowing tumors to grow more effectively. Our preliminary findings show that PSGL-1 is highly expressed on myeloid cells within melanoma tumors. In experiments with mice lacking PSGL-1 in these immune cells, we observed better control of tumor growth and stronger immune responses.Overall, this study aims to clarify the role of PSGL-1 in myeloid cells, potentially leading to novel treatments that improve the immune system’s ability to combat melanoma. By targeting this molecule, we hope to develop strategies that can enhance anti-tumor immunity, offering new hope for patients with limited treatment options.

Discovery of Molecular and Cellular Biomarkers for the Malignant Transformation of Conjunctival Melanocytic Intraepithelial Lesions
Investigator
Rui Chen,
PhD, Department of Ophthalmology, UC Irvine School of Medicine
Melanocytic neoplasms are not always unequivocally classified as either benign or malignant. A subset of intermediate lesions, usually detected by histologic assessment, demonstrate ambiguous morphological features, requiring molecular analysis for further characterization. We propose to identify early molecular alterations and cellular biomarkers to improve the classification of C-MIL and determine the risk of malignant transformation.

Targeting Piezo1 Channels to Improve CD8 T Cell-mediated Solid Tumor Immunity
Investigator
Shivashankar Othy
, PhD, Department of Physiology and Biophysics, UC Irvine School of Medicine
Solid tumors, which make up the vast majority (~90%) of adult cancers, are challenging to attack using immunotherapies because the stiff tissue environment excludes immune cells and limits their ability to kill tumor cells. Our project is highly relevant to cancer research because we will define the fundamental mechanisms by which CD8 T cells (essential tumor-killing cells) sense and respond to the mechanical properties of solid tumors. Our studies will evaluate Piezo1, a mechanosensing ion channel, as a potential therapeutic target (mechanical checkpoint) to overcome barriers to CD8 T cell function in stiff tissues, with broad applicability across various forms of solid tumors affecting people from all backgrounds, ethnicities, and socioeconomic statuses. In the big picture, a better understanding of the role of biomechanical signals in regulating the immune system in solid tumors will transform the rapidly evolving cancer immunotherapies and improve the quality of life of millions of individuals with solid cancers.

Sleep Health among Young Adult Cancer Survivors
Investigator
Sunmin Lee,
PhD, Department of Medicine, UC Irvine School of Medicine
This pilot study will generate critical preliminary data to guide future sleep intervention study among young adult cancer survivors in Southern California. Results will help identify the prevalence of sleep disturbance, specific sleep-related late effects that may disproportionately affect this population and provide an in-depth understanding of sleep difficulties.
 
Robotic-Guided Optical Coherence Tomography for Real-Time Evaluation of Peripheral Pulmonary Nodules in Early Lung Cancer Detection
Investigators
Thomas W Waddington, MD,
Department of Medicine, UC Irvine School of Medicine
Zhongping Chen, PhD, Department of Biomedical Engineering, UC Irvine Samueli School of Engineering
Lung cancer remains the leading cause of cancer-related death, and many patients undergo invasive biopsies to determine whether a lung nodule is cancerous. Current imaging methods can locate nodules but cannot provide detailed structural information before tissue is removed, exposing patients to risks such as bleeding or lung collapse. This project will integrate a high-resolution optical imaging technology with robotic bronchoscopy to allow physicians to visualize microscopic tissue features in real time during evaluation. By improving early and more precise assessment of lung nodules, this approach may reduce unnecessary procedures and enhance the safety and accuracy of lung cancer diagnosis
 
Feasibility Study of Long-Term Adolescent/Young Adult Hodgkin Lymphoma Survivors
Investigator
Wendy Cozen, DO, MPH,
, Department of Medicine, UC Irvine School of Medicine
This proposal has community relevance for providing pilot data for a larger R01 grant to understand and mitigate late effects that can negatively impact the quality of life of long-term adolescent/young adult Hodgkin lymphoma survivors. We will also test samples that were collected near the time of diagnosis (up to 18 years ago) to determine if they are still viable for additional studies to evaluate immune function and its impact on late effects. Results will provide critical information to leverage samples and data collected for a study decades ago, to identify determinants at or near the time of diagnosis of future adverse late effects among long-term survivors. AYA cancers and survivorship are priority areas for the CFCCC, and this proposal addresses these topics with a novel resource and new Cancer Control Program collaborations.

Establishing a spatial-genomics based cancer neuroscience platform to map neural–tumor interactions in human cancers
Investigator
Xiangmin Xu, PhD, Department of Anatomy & Neurobiology, UC Irvine School of Medicine
Cancer remains a major health challenge in Orange County and beyond; improving early diagnosis and treatment are critical for better patient outcomes. This project will develop new approaches to study how cancer cells interact with neural elements within tumors, an emerging area of research that may influence how cancers grow and respond to treatment – and will impact UCI Health patients first as this knowledge is generated here. By applying advanced spatial genomics technologies to tumor samples from patients, the study aims to identify new biomarkers that could improve cancer diagnosis and guide more personalized therapies. The knowledge generated from this research may ultimately contribute to better diagnostic tools and more effective treatments for cancer patients in our community.
​
Soluble Matrisomics to Identify Druggable Targets for Stroma-Directed Cancer Therapy
Investigator
Xiaoyu Shi, PhD,
Department of Developmental & Cell Biology, UC Irvine School of Biological Sciences
Aggressive cancers like pancreatic and breast cancer are difficult to treat because they are surrounded by a dense "shell" of structural proteins and signaling molecules that block drugs and help the tumor grow. This research project develops a new technology called GEM-ECM to map these surrounding proteins, specifically targeting the hidden signaling factors that traditional methods often discard. By identifying these accessible targets, this work will pave the way for new therapies that can bypass the tumor's defenses and lead to novel treatment and earlier, non-invasive diagnosis. Ultimately, this project aims to improve survival rates for patients with hard-to-treat solid tumors by turning the tumor's own environment into a roadmap for more effective treatments.
 
UHRF1 as a Novel Regulator of Proteasome Function and Tumor Cell Fitness
Investigator
Claudia Benavente,
PhD, Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy and Pharmaceutical Sciences
Cancer cells rely on efficient protein quality control to survive proteotoxic stress driven by oncogenic signaling and rapid proliferation. The ubiquitin-proteasome system, and specifically the 26S proteasome, is the primary pathway responsible for selective protein degradation; however, the molecular mechanisms that regulate proteasome function in solid tumors remain incompletely defined. UHRF1 is a multidomain protein frequently overexpressed in aggressive cancers and classically associated with DNA methylation and chromatin regulation. Emerging evidence indicates that UHRF1 may also associate with proteasome complexes through a ubiquitination-independent mechanism, suggesting a previously unrecognized role in proteostasis. This project will test the hypothesis that UHRF1 functions as a regulatory component of the proteasome that enhances proteasome assembly and/or activity, thereby promoting tumor cell fitness. Aim 1 will define the molecular interface between UHRF1 and proteasome complexes using domain-mapping and biochemical approaches. Aim 2 will determine whether UHRF1 regulates proteasome assembly and catalytic function, including ubiquit independent substrate degradation. Aim 3 will evaluate the contribution of UHRF1-dependent proteasome regulation to tumor cell fitness and proteostasis under stress conditions. These studies will establish a mechanistic framework linking UHRF1 to protein degradation and define a novel regulatory axis in cancer biology. The findings are expected to reveal new insights into how tumor cells modulate proteasome function and may identify vulnerabilities that can be exploited therapeutically in aggressive cancers.

2025 TRACK 2: EARLY PHASE CLINICAL TRIALS

Circulating Tumor DNA (ctDNA) as a Biomarker for Total Neoadjuvant Therapy in Stage III Melanoma      
Investigator

Poorva Vaidya, MD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
In Stage III melanoma, pre-operative immunotherapy confers a recurrence free survival benefit and yields a pathologic complete response rate close to 50%; however, it remains unknown how many cycles of treatment are optimal prior to surgery and if levels of circulating tumor DNA (ctDNA) inform duration of treatment. We aim to answer both questions in this clinical trial titled “Total Neoadjuvant Therapy for Melanoma.” Melanoma highly impacts the patient population treated at Chao Family Comprehensive Cancer center and further elucidating the role of pre-operative immunotherapy in its treatment will meet a large clinical need for UC Irvine’s catchment area.

Phase 1B Randomized Study of Gemcitabine (G) with or without Pitavastatin (P) in the maintenance treatment of unresectable pancreatic adenocarcinoma (uPDAC)
Investigator

Jennifer Valerin, MD, PhD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer-related death in the United States and projected to be the second leading cause by 2030. Gemcitabine is the most commonly used chemotherapy PDAC. However, cells can become resistant to gemcitabine and pitavastatin, a medication to treat high cholesterol has been shown to prevent resistance. Here we plan a clinical trial to combine gemcitabine therapies and pitavastatin to improve cancer outcomes.
 

2024 Funded Research

2024 TRACK 1: PILOT PROJECTS

Identifying Cellular Mechanisms of Resistance to Radioimmunotherapy 
Investigator
Aimee Edinger, PhD, VMD, Department of Developmental & Cell Biology, UC Irvine Charlie Dunlop School of Biological Sciences
This proposal seeks to improve the effectiveness of radiation therapy in the treatment of breast cancer, a tumor type with a high rate of incidence in Orange County. It is focused on developing new therapeutic approaches that will improve the response of lethal, treatment-resistant and metastatic tumors to radiation therapy and to the combination of radiation therapy and treatments that target the immune system. In the long term, this project could lead to clinical trials for new treatment protocols that could cure primary tumors and even metastatic disease in breast cancer patients and in other cancer classes such as pancreatic cancer and colorectal cancer.

Evaluating Patient and Provider Experience with Lung Cancer Screening False Positive Results
Investigator
Amir Imanzadeh, MD, Department of Radiological Sciences, UC Irvine School of Medicine

Lung cancer screening (LCS) is essential for early detection, yet disparities persist in our community, with many underserved and minority populations not receiving recommended screenings. False positive (FP) results can further discourage participation, exacerbating these disparities. This study aims to understand the impact of FP results on patient adherence and provider management, ultimately informing strategies to enhance LCS access and acceptance. By addressing these challenges, our work has the potential to promote equitable screening  practices and improve lung cancer outcomes across the entire community, especially for those who need it most.

Advancing Equitable Precision Medicine in Cardio-Oncology: Machine Learning Based Prediction of TKI-Induced Arrhythmias in Patients with Lung Cancer
Supported by Team Answer for Cancer
Investigator
Aya Ozaki, PharmD, Department of Clinical Pharmacy, UC Irvine School of Pharmacy & Pharmaceutical Sciences

Tyrosine kinase inhibitors (TKIs) are important cancer treatments, but they can cause serious heart problems, including abnormal heart rhythms. This project uses artificial intelligence (AI) machine learning to predict which lung cancer patients are at risk for these complications, helping doctors make safer treatment decisions. By including social and economic factors, this study ensures that risk predictions are fair and useful for all patients, including those from underserved communities. The findings will help improve cancer care and reduce heart-related side effects, ultimately leading to better health outcomes for patients.

The Cancer-Plasma Metabolome Atlas (TCMA) project
Investigator
Cholsoon Jang, PhD, Department of Biological Chemistry, UC Irvine School of Medicine

This research project aims to create a detailed map of chemicals found in the blood of younger cancer patients  with five common cancer types. By analyzing these blood samples and comparing them to those from healthy individuals, researchers hope to identify unique chemical patterns for each cancer type. These patterns could  lead to improved early detection methods, more personalized treatments, and better ways to monitor treatment  effectiveness. Ultimately, this research has the potential to significantly improve cancer care, potentially saving  lives and enhancing the quality of life for cancer patients and their families.

Defining UHRF1 as a Key Factor in Pancreatic Cancer Development and Treatment
Supported by Team Answer for Cancer
Investigator
Chris Halbrook, PhD, Department of Molecular Biology and Biochemistry,
UC Irvine Charlie Dunlop School of Biological Sciences

Pancreatic cancer is one of the deadliest major cancers with no effective therapeutic strategies. A barrier to the  development of new treatments has been a poor understanding of the key factors driving the initiation of this disease. Working with Dr. Claudia Benavente at UC Irvine, we have discovered a protein called UHRF1 is essential  to pancreatic cancer development and has been proposed as a potential therapeutic target in several other cancer types. Using cutting-edge models and technologies, we will uncover how UHRF1 allows tumors to form  in the pancreas and demonstrate its ability to be an actionable target in pancreatic cancer treatment.

Development of an Intelligent Chatbot to Aid Quit-Smoking Support Groups
Investigator
Connie Pechmann, PhD, MBA, MS, UC Irvine Paul Merage School of Business
This research aims to enhance the performance of a chatbot to assist individuals in small, private, online, peer support groups for quitting smoking, addressing the challenge of delayed responses when human members are unavailable. The chatbot, driven by Artificial Intelligence (AI), identifies the common post types or topics discussed in the support groups and generates a variety of engaging responses. This project aims to enhance the chatbot's accuracy at comprehending user posts by incorporating more relevant training data. By refining the chatbot and bolstering its accuracy, we aim to increase engagement in the support groups, both  peer-to-chatbot and peer-to-peer, thus improving quit rates, with significant implications for public health.

Immunoproteasome-Mediated Release of MMAE as a Prodrug Strategy for SCLC Treatment

Investigators
Darci Trader, PhD, Department of Pharmaceutical Sciences, UCI School of Pharmacy and Pharmaceutical Sciences
Claudia Benavente, PhD
(Co-Principal Investigator), Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy and Pharmaceutical Sciences
Lung cancer is one of the deadliest types of cancer, and small cell lung cancer (SCLC) is its most aggressive form. SCLC spreads quickly, is often diagnosed at an advanced stage, and has limited treatment options. Our study focuses on the development of a new mechanism to deliver powerful chemotherapy directly to cancer  cells, while sparing healthy cells. If successful, our work could lead to longer survival rates, improved quality of life for patients, and new strategies for fighting other hard-to-treat cancers.
 
Developing Treatments for Multi-Organ Metastasis
Investigator
Devon Lawson, PhD, Department of Physiology and Biophysics, UC Irvine School of Medicine

Metastasis frequently affects not only one, but several organs in breast cancer patients. Multi-organ metastasis  is very difficult to treat and is associated with high mortality rates. Identifying common features of metastasis  in different metastatic organs may reveal novel strategies to target metastasis systemically. Using an innovative  new method for analysis of the tissue microenvironment by single cell genomics, we found that metastatic  tumors in each organ (brain, liver, lung, and bone) contain the same type of immune cell called macrophages. We found that these macrophages promote metastatic tumor growth by suppressing the immune system. Further analysis identified a specific pathway expressed by the macrophages and cancer cells in each organ,  called MIF-CD74. In the next phase of this project, we will test whether drugs that target this pathway (MIF inhibitor CPSI-1306; anti-CD74 small peptide C36L1) can treat multi-organ metastasis in pre-clinical models of breast cancer. 
 
Optimization of Checkpoint Immunotherapy Using Biological and Mathematical Models

Investigators
Francesco Marangoni, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
John Lowengrub, PhD (Co-Principal Investigator), Department of Mathematics, UC Irvine School of Physical Sciences
The interplay between many immune reactions, drug dosage, and timing of administration determines the  efficacy of checkpoint blockade immunotherapy against cancer. These variables are so numerous that the exploration of their combinations to find optimal immunotherapy regimens is prohibitively resource- and time consuming. In this Anti-Cancer Challenge proposal, we will use a newly developed mathematical model  of immune reactions in tumors, followed by experimental validation of predictions, to identify an  immunotherapy regimen bearing maximal efficacy against melanoma, which is a highly prevalent cancer in our catchment area. More generally, we aim at developing math-aided immunological research to accelerate  the discovery of new anti-cancer strategies.
 
Systematic Investigation of Sphingolipid Mimetics as Anti-Neoplastic Leads
Investigator
Glenn Micalizio, PhD, Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy and Pharmaceutical Sciences
Studies conducted by the Edinger laboratory have shown that sphingosine mimetics would be ideal to address cancers with unusually high incidence, prevalence, and/or mortality in Orange County such as melanoma, breast, and lung cancer, doing so in a manner that would overcome common chemotherapeutic resistance mechanisms. My expertise in molecular science is proposed as a means to drive systematic investigation of molecular perturbations within a sphingosine mimetic structure to determine a path toward establishing a therapeutically relevant lead with potency 10–100x greater than their current “best” compounds. My laboratory has expertise in pursuits that are molecularly related to the challenge here, with efforts previously  being focused on the design and synthesis of fatty acid mimetics as potent and selective modulators of several  therapeutically relevant receptors (ToxT – a transcription factor required for virulence in cholera, GPR40 – a receptor of interest in the development of therapeutics for diabetes, and TLX – a nuclear receptor thought to be a modern target for a range of neurodegenerative conditions). 
 
Spatially Engineered In Vitro Models to Screen Structural Cardiotoxicity Induced by Anti-Cancer Therapeutics
Investigator
Herdeline Ann Ardona, PhD, Department of Chemical and Biomolecular Engineering, UC Irvine Samueli School of Engineering
Advancements in chemotherapeutic drugs have successfully raised the survival rates of cancer patients in  recent years. However, while a cancer patient may survive the treatments, many could suffer from the life threatening cardiovascular risks imposed by these drugs. Proposed here is the development of lab-grown models of cardiac tissues to screen individualized, patient-specific effects of cancer drugs on the structure and health of heart tissues.

Early Support Feasibility for Patients with Advanced Ovarian Cancer

Investigator
Jacqueline Kim, PhD, Department of Medicine-Hematology/Oncology, UC Irvine School of Medicine

Evidence-based psychotherapeutic interventions are needed to help patients with advanced cancer, such as ovarian cancer, to manage the multiple psychological sequelae of these conditions. This pilot study will inform the development of a larger randomized controlled trial to demonstrate the effectiveness of a novel intervention to reduce symptoms of traumatic stress and depression in women with ovarian cancer. 
 
Therapeutic Potential of EGFR-CAR T9 Cells Deficient in the m6A RNA Reader Protein
Investigators
Jianhua Yu, PhD, Department of Medicine, UC Irvine School of Medicine

Alexander Minella, MD (Co-Principal Investigator), Division of Hematology/Oncology, Department of Clinical Medicine, UC Irvine School of Medicine
Glioblastoma (GBM) is the most aggressive and deadly form of brain cancer, with limited effective treatment  options. This project aims to develop an advanced immune cell therapy using CAR T9 cells, engineered to stay active longer and resist exhaustion for improved tumor-fighting ability. By investigating how the gene YTHDF2 regulates these immune cells, the goal is to enhance CAR T9 cell efficacy against GBM and improve treatment  outcomes. If successful, this research could lead to a more potent and durable immunotherapy for GBM patients, offering new hope where current treatments fall short.
 
Preclinical Validation of a Multi-Targeted TKI in Combination Therapy for Endometrial Cancer

Investigators
Jill Tseng, MD, Department of Obstetrics and Gynecology, UC Irvine School of Medicine
David Fruman, PhD (Co-Principal Investigator), Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
Chris Halbrook, PhD (Co-Principal Investigator), Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences

The United States Cancer Statistics (USCS) data from 2001 to 2017 demonstrated that the overall incidence of uterine cancer was 27.5 vs. 23.3 per 100,000 in Hispanic vs. White people, with Hispanic patients having a higher incidence of Stage III or IV disease at diagnosis. Moreover, 34.2% of the population of Orange County, California identifies as Hispanic, with endometrial cancer being the second most prevalent new cancer diagnosis among females in this population. UC Irvine cares for many endometrial cancer patients with recurrent/metastatic disease, most of whom represent minority populations. The results of this preclinical study  will direct a subsequent phase I/II trial here at UC Irvine, which would not only provide additional therapeutic options for patients within our community but would also bolster opportunities for minority population enrollment in UC Irvine clinical trials.
 
Comparing Symptom Clusters between Early-Onset and Late-Onset Colorectal Cancer: Improving Early Identification and Treatment Access Using Real-World Data
Investigator
Joel Milam, PhD, Department of Epidemiology and Biostatistics, UC Irvine Joe C. Wen School of Population & Public Health

This study, focusing on members of the UC healthcare system, addresses the rise in colorectal cancer (CRC) among young adults, a trend that warrants further investigation. Raising awareness at the community level about  EOCRC, particularly among diverse populations, is crucial. Results will inform early detection and diagnosis efforts that are vital for improving quality-adjusted life years (QALYs) for young adults facing this disease.
 
Functional Validation of AlphaFold-Predicted GLI-SUFU Contacts: Implications for Medulloblastoma and Other Diseases

Investigator
Lee Bardwell, PhD, Department of Developmental & Cell Biology, UC Irvine Charlie Dunlop School of Biological Sciences
Mutations in the SUFU gene predispose to medulloblastoma, the most frequent brain tumor in infants and young children. SUFU mutations are also found in patients with the hereditary disease Gorlin syndrome, and in other  more common cancers, including basal cell carcinoma, the most common cancer in Orange county and the USA. SUFU protein plays a key role in inhibiting the activity of the GLI factors, which are encoded by genes that are also mutated in cancer and hereditary diseases. Our study aims to further understand the SUFU-GLI  interaction in order to better predict the effect of mutations in patients. By linking predictive AI, biochemical experiments and clinical data, our findings have the potential to inform therapeutic strategies in  medulloblastoma, Gorlin syndrome and other diseases.
 
Enhancing GlyTR Cancer Killing by Metabolically Increasing Target Expression 

Investigator
Michael Demetriou, MD, PhD, Departments of Neurology and Microbiology & Molecular Genetics, UC Irvine School of Medicine
Prognosis is abysmal for patients with advanced solid tumors and there is an urgent unmet need for novel  mechanisms of action and additional paradigm shifting therapeutic options. Triggering immune cells to bind and kill cancer cells is a highly potent way of treating liquid cancers, but has been unsuccessful in solid cancers due to lack of binding targets and immunosuppression. To address this issue we have developed novel technology termed GlyTR (pronounced ‘glitter’) that can safely target the vast majority of cancer types for killing by immune  cells. Here we propose to maximize GlyTR killing activity by metabolically enhancing target expression in cancer cells.

 
Lineage Tracing of Breast Cancer Metastasis-Initiating Cells
Investigators
Olga Razorenova, PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
Qing Nie, PhD (Co-Principal Investigator), UC Irvine School of Physical Sciences and UC Irvine Charlie Dunlop School of Biological Sciences
Theresa Loveless, PhD (Co-Principal Investigator), Department of Biosciences, Rice University
Shaheen Sikandar, PhD (Co-Principal Investigator), Department of Molecular, Cell & Developmental Biology, UC Santa Cruz
First study to use state of the art technology to determine ancestry tree of tumor cells and metastases in breast cancer patient-centric animal models. Our study will address the gap in knowledge of how cancer stem cells drive tumor progression towards metastasis. This knowledge will advance therapeutic and  biomarker development.
 
Developing a Cell-Based DEL Screen for Pan-Mutant p53 Corrector Compounds

Investigators
Peter Kaiser, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
Brian Paegel, PhD (Co-Principal Investigator), Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy and Pharmaceutical Sciences
Many cancers have a faulty version of a protein called p53, which normally helps protect against tumor growth. Scientists are working to find new medicines that can fix or reactivate this damaged protein, giving it back its  ability to stop cancer. Our project will use a special screening technology to rapidly test thousands of potential drug candidates to find the most promising ones. If successful, this research could lead to new treatments that  help many cancer patients whose tumors have p53 mutations.

Elucidating the Oncobiology of Exportin 7 and its Utility as a Biomarker and Therapeutic Target in Cholangiocarcinoma 

Investigator
Reed Ayabe, MD, Department of Surgery, UC Irvine School of Medicine

The incidence of bile duct cancer, or cholangiocarcinoma, is rising and affects a disproportionately large number of Asian and non-White Hispanic patients in Orange County. This research will focus on a protein called XPO7 that is upregulated in patients with cholangiocarcinoma and may have both diagnostic and therapeutic value. Understanding how XPO7 functions in the development and spread of cholangiocarcinoma may lead to the discovery of new tests to diagnose this disease earlier, as well as new therapies for a disease that has very  limited treatment options. This work will benefit a growing body of patients with biliary tract cancer and is of particular relevance to the patients we treat every day at UC Irvine.

Unraveling the Role of smPHLDA3 and LINK in Cancer

Investigators
Remi Buisson, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
Thomas Martinez, PhD (Co-Principal Investigator), Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy & Pharmaceutical Sciences
Tumor heterogeneity, or variation within a tumor, is the main cause of resistance to current chemotherapy drugs  as well as metastasis development, leading to patients’ deaths. Within the same tumor from the same patient, tumor cells might be subtly or even dramatically different, making it harder to treat clinically. Understanding the mechanisms driving cancer diversity is a critical step toward developing new strategies to attenuate tumor evolution and adaptation. DNA damages caused by UV exposure or other environmental factors are the main cause of genomic instability leading to cancer initiation and tumor heterogeneity. Therefore, maintaining the integrity of DNA and ensuring that DNA damage is repaired effectively is critical in reducing the risk of cancer.  In this study, we propose to identify and characterize new factors that are essential to repairing DNA damage  and maintaining the genetic information of the cells.
.
Pacific Islander Healthy Eating Active Living Intervention Development (PI HEAL-ID)
Investigator
Sora Tanjasiri, DrPH, Department of Epidemiology and Biostatistics, UC Irvine Joe C. Wen School of Population & Public Health
Obesity, physical activity and nutrition are estimated to contribute to nearly 20% of all cancer incidence, and Pacific Islanders (PIs) have higher proportions of obesity compared to the general population. To reduce the burden of cancer among Pacific Islanders (PIs), community-based preventative strategies that  focus on healthy lifestyles are needed, yet few exist that are sustainable in these often-low income populations. This proposed study will leverage ties to PI community experts to adapt two lifestyle interventions into one  prototype, and learn from PI community members the barriers and facilitators to lifestyle adoption that are  necessary to plan for relevance and sustainability. This will result in a prototype intervention to be tested in a  future community randomized study to reduce cancer related risks in this vulnerable population.

Unleashing Innate Immunity with Novel STING and TLR Agonist Prodrugs

Investigators
Vy Dong, PhD, Department of Chemistry, UC Irvine School of Physical Sciences
Thomas Burke, PhD (Co-Principal Investigator), Department of Microbiology and Molecular Genetics, UC Irvine School of Medicine
This proposal is to develop new small molecule anti-cancer drugs to treat a variety of solid tumor indications. These novel drugs target multiple arms of the innate immune system and therefore work in concert with existing immunotherapies that activate adaptive immunity, including FDA-approved checkpoint inhibitors. These efforts will aid public health by establishing new frameworks for how to simultaneously target multiple arms of innate immunity and by advancing novel anti-cancer drugs towards the clinic.

Deciphering STK38/L-mediated Hippo Pathway Dysregulation in Ovarian Cancer
Investigator
Wenqi Wang, PhD, Department of Developmental and Cell Biology, UC Irvine Charlie Dunlop School of Biological Sciences
Ovarian cancer is a deadly disease with limited treatment options. The Hippo pathway is a critical system  that normally prevents uncontrolled cell growth, whose dysregulation is often associated with ovarian cancer development. Our research suggests that two proteins STK38 and STK38L inactivate the Hippo pathway in  ovarian cancer, allowing tumor cells to grow uncontrollably. In this application, we aim to investigate how STK38  and STK38L contribute to ovarian cancer progression by affecting the Hippo pathway and explore whether targeting them could be a new treatment approach for ovarian cancer treatment.

 

2024 TRACK 2: EARLY PHASE CLINICAL TRIALS

Treating Anemia in Myelofibrosis with Repurposed Drugs that Inhibit Furin to Block Cleavage of Prohepcidin to Hepcidin
Investigator
Angela Fleischman, MD, PhD,  Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Increased amounts of the hormone hepcidin drives inflammation induced anemia by restricting the body’s ability  to utilize iron. Patients with the uncurable blood cancer Myelofibrosis suffer from anemia of chronic inflammation  and high hepcidin, so reducing hepcidin should improve anemia in this condition. Nelfinavir, a drug currently used to treat HIV blocks the activation of hepcidin under inflamed conditions and this treatment restores iron delivery to the bone marrow in animal models. In a clinical trial with Myelofibrosis patients we will test whether  a 30-day course of Nelfinavir reduces hepcidin and restores iron delivery to the bone marrow allowing for improved red blood cell production. The impact of this research will be a treatment that will alleviate the anemia  present in Myelofibrosis and improve the quality of life of these patients.
 
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy: A Pilot Feasibility Clinical Trial
Investigator
Gelareh Sadigh, MD, Department of Radiological Sciences, UC Irvine School of Medicine
New oral anticancer treatments have improved survival across cancer types but introduced challenges in medication adherence and symptom management. Our study will test a new mobile health intervention that  facilitates remote adherence and symptom monitoring, patient-provider communication outside of clinic visits regarding the use of the OAT, and financial and social need support as well as health literacy support for  those in need among 30 English- and Spanish- speaking patients. Our study will increase our understanding of barriers and facilitators to use of the proposed mobile health intervention.


A Phase I Study of the Application of Lattice Adaptive Radiotherapy Protocol (LARP) for Symptomatic, Bulky Tumors
Investigator
Jeremy Harris, MD, Department of Radiological Sciences, UC Irvine School of Medicine
Lattice radiation is a form of spatially fractionated radiation that integrates alternating areas of hot and cold spots throughout the tumor volume, resulting in a more favorable immune response and surprisingly impressive tumor shrinking. We propose a phase I clinical trial to test the safety of Lattice Adaptive Radiotherapy Protocol (LARP), which will incorporate an emerging technology that creates a new radiation plan with each day of treatment. If successful, the proposed study will help to establish a novel therapy for bulky tumors, with clinical applications for patients with both metastatic disease as well as tumors too large to be safely resected.
 
Feasibility Study of a Couples Intervention for Young Adult Cancer Survivors
Investigator
Michael Hoyt, PhD, Department of Population Health and Disease Prevention, UC Irvine Joe C. Wen School of Population & Public Health
Establishing the ability to test the GET-C intervention to a broader population of young adult survivors expands the ability to meet the needs of a larger portion of our catchment area populations. The current study  also increases the opportunities to partner with CHOC in the current project and the future clinical trial. This  project will progress this work along the translational spectrum and is a necessary precursor to testing efficacy in a more representative population.

UCI 19-145: Phase II, Open-Labeled, Single-Armed Combination Treatment with Anastrozole, Fulvestrant and Abemaciclib for Hormone Receptor Positive, HER2(-) Metastatic Breast Cancer

Supported by Team Answer for Cancer
Investigator
Rita Mehta, MD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Breast cancer is a leading health concern in Orange County, with the highest rates of diagnosis and  death among women. Many patients with hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) eventually develop resistance to standard hormone-based treatments, limiting long-term disease control and survival. Building on prior research showing survival benefits from combination hormonal therapy, this study explores whether adding a CDK4/6 inhibitor (abemaciclib) to anastrozole and fulvestrant can further improve patient outcomes. With additional support, this research could lead to identifying more  effective treatments, offering better and longer-lasting outcomes for those facing MBC.

Metronomic Cyclophosphamide with Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Supported by Team Answer for Cancer
Investigator
Warren Chow, MD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Melanoma will be the 5th most diagnosed cancer in 2025, and oral agents targeting B-RAF mutation present in ~50% of melanomas and immunotherapy blocking (anti-) CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and  nivolumab) for those tumors regardless of B-RAF mutations have significantly improved the outcome for this  previously difficult-to-treat cancer. Patients who either fail to respond to primary anti-PD-1 therapy or progress  after initial response have a poor prognosis. Cyclophosphamide (CTX) is one of the oldest anticancer chemotherapy agents, and transiently eliminates various subsets of immune suppressive white blood cells while  increasing activity of pro-immune cells. Metronomic dosing is the frequent, even daily, administration of  anticancer chemotherapeutic drugs at doses significantly less than the maximum dose with minimal side effects. Metronomic CTX has now been shown to reverse immune suppression by the cancer and promote immune  rejection of cancer. Accordingly, in this non-placebo clinical trial, we will determine the response rate and  duration of no cancer growth for the combination of oral daily metronomic CTX and every 3 week IV  pembrolizumab in pembrolizumab-resistant advanced or metastatic melanoma. Successful completion of  this trial would make metronomic CTX and pembrolizumab an appealing option for pembrolizumab-resistant melanoma.

Non-Invasive Optical Imaging for Prognostication and Assessment of Treatment Response in Mycosis Fungoides
Investigator
Xiying Fan, PhD, MD, Department of Dermatology, UC Irvine School of Medicine
Currently, skin biopsies are the only method to identify microscopic features that predict more aggressive disease in patients with mycosis fungoides, the most common type of skin lymphoma. However, multiple biopsies are often needed, and they generally cannot be repeated on the same area, limiting their use for  monitoring treatment. This highlights the need for non-invasive alternatives for assessing skin lymphomas. The goal of this project is to evaluate how well two types of non-invasive imaging devices can detect  aggressive disease features or predict treatment response. If successful, these imaging technologies could be widely implemented to guide treatment decisions and predict outcomes for patients with skin lymphomas.

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients with Solid Tumors
Investigators
Zhaohui Arter, MD,
Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Cholsoon Jang, PhD (Co-Principal Investigator), Department of Biological Chemistry, UC Irvine School of Medicine
Peter Kaiser, PhD
(Co-Principal Investigator), Department of Biological Chemistry, UC Irvine School of Medicine
This Phase 0 clinical trial aims to assess the feasibility of a methionine-reduced diet in cancer patients,  translating promising findings from UCI basic science research into clinical practice. Methionine, an essential amino acid, supports cancer cell growth, and preclinical studies suggest that restricting its intake could slow  tumor progression and enhance the effectiveness of cancer treatments. This trial will determine whether patients can adhere to the diet and measure its initial effects on their health. The results from this study will lay the foundation for future Phase I/II trials, directly evaluating whether dietary methionine restriction can improve cancer treatment outcomes.

2023 Funded Research

2023 TRACK 1: PILOT PROJECTS

Establishment of a Model System to Elucidate Mechanisms of Response and Resistance to Engineered T-cell Therapy in Lymphoma
Investigator
Brian Sworder, MD, PhD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Immune based treatment strategies are increasingly employed to treat patients with non-Hodgkin lymphoma (NHL), but many patients still experience relapse. In this study we seek to develop of method through which we can better understand how mutations in particular genes contribute to treatment resistance following a particular type of immune based therapy called chimeric antigen receptor (CAR) T-cells. If successful, this project will build a foundation for future clinical trials by informing the development of improved immunotherapies for this illness and improve outcomes for patients.

Investigation of Microprotein Contributions to Pancreatic Ductal Adenocarcinoma
Investigator
Thomas Martinez, PhD, Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy & Pharmaceutical Sciences

The identification and characterization of all proteins encoded in the human genome is critical for understanding both normal physiology and disease. Here we will investigate how a class of previously overlooked small proteins impact tumor growth in pancreatic ductal adenocarcinoma. By uncovering novel regulators of tumor growth, we hope to enable the discovery of targeted therapeutics and biomarkers for early diagnosis of this incredibly lethal disease.

Targeting Neoplastic Cell Fate Transitions Through Adhesome Signaling
Investigator
Timothy Downing, PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
Our research aims to develop a groundbreaking platform technology that can reveal how cancer cells change over time and in response to treatment. By studying these changes, we hope to identify new ways to treat cancer more effectively and prevent relapse. This innovative approach could lead to personalized treatment options and ultimately improve outcomes and overcome health disparities for cancer patients in our community and around the world.

 
Exploring Lipid Metabolism in NAFLD-HCC Transition Using Stem Cell Derived Hepatocytes

Investigator
Quinton Smith, PhD, Department of Chemical and Biomolecular Engineering, UC Irvine Samueli School of Engineering

Our research investigates how changes in fat processing within liver cells contribute to the development of liver cancer. We aim to understand how exposure to certain fats, similar to those associated with a common liver disease called NAFLD, affects the behavior of liver cells derived from stem cells. By studying this, we hope to uncover the underlying mechanisms that drive liver cancer development from metabolic dysfunction. Additionally, we will use advanced genetic techniques to introduce specific genetic changes associated with a higher risk of liver disease found in Hispanic populations, to shed light on how genetic factors influencing likelihood of cancer development.

Innovative Approaches to Address Chemoresistance in Prostate Cancer: Integrating Electrokinetic and Microfluidic Technologies
Investigator
Tayloria Adams, PhD, Department of Chemical and Biomolecular Engineering, UC Irvine Samueli School of Engineering
Our research project aims to develop innovative methods to combat chemoresistance in prostate cancer, a disease that disproportionately affects African American men, who experience higher rates of incidence and mortality. By utilizing advanced engineering techniques to study the physical properties of cancer cells and their response to treatment, we seek to understand the underlying mechanisms of chemoresistance. This research is crucial for addressing health disparities and enhancing our understanding of prostate cancer biology, leading to the development of targeted therapeutic interventions. Ultimately, our findings could lead to improved treatment strategies for all individuals affected by prostate cancer, particularly those from marginalized communities, potentially extending and enhancing their quality of life.

Financial Implications of a Pediatric/Adolescent/Young Adult (AYA) Cancer Diagnosis on a Patient’s Quality of Life and Health Outcomes
Supported by Team Answer for Cancer

Investigator
Sonia Morales, MD, MPH, Department of Pediatrics, UC Irvine School of Medicine
Pediatric and adolescent/young adult (AYA) cancer survivors, along with their families, often face financial hardships. To evaluate the health outcomes and financial implications on pediatric/AYA patients with cancer and their parents, longitudinal data is needed, particularly in a culturally diverse population. This study seeks to investigate and characterize how financial hardship correlates to decreased care nonadherence, increased psychological distress and educational/vocational status among pediatric/AYA cancer patients.
 
HMGB2 Regulation of Anti-Tumor T cell Immunity
Investigator
Roberto Tinoco, PhD, Department of Molecular Biology and Biochemistry, UC Irvine School of Biological Sciences
Few cancer patients respond to current immunotherapies, highlighting the pressing need to identify, develop, and improve treatments that are efficient and safe for patients that presently have no treatment options. The proposed studies will determine whether a new protein in T cells is essential for their ability to kill cancer cells. If successful, the study may lead to new drugs that may improve therapies for cancer patients.
 
A Novel Gut-Liver Axis as a Risk Factor for Liver Cancer
Investigator
Cholsoon Jang, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
There is a concerning surge in the incidence of liver cancer in Orange County. Latino populations are particularly prone to developing liver cancer, partly due to their high consumption of dietary fructose, which causes fatty liver disease and eventually leads to liver cancer. However, not all individuals who consume excessive fructose develop liver cancer, underscoring the existence of key inherent factors that increase liver cancer susceptibility. This proposal aims to identify such factors and associated molecular mechanisms, eventually to reduce liver cancer incidence for vulnerable individuals.
 
Estrogen-Induced Oncogenic RNA Translation in Young Women's Tumors
Investigators
Gina Lee, PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
Thomas Martinez, PhD, (Co-Investigator), Department of Pharmaceutical Sciences, UC Irvine School of Pharmacy & Pharmaceutical Sciences
In young women of childbearing age with elevated estrogen levels, a tumor syndrome known as LAM can cause uncontrolled cell growth in the kidneys and lungs. The current therapeutic drug for LAM, rapamycin, often induces severe side effects and exhibits limited effectiveness in tumor removal. This proposal aims to elucidate a novel signaling pathway that enhances the tumorigenic growth of LAM cells, particularly in the presence of estrogen. The efficacy of a new therapeutic drug targeting this pathway will be tested in pre-clinical mouse models and patient cells. The success of this project has the potential to transform LAM treatment and offer insights into other hormone-induced women's cancers, including breast and ovarian cancers.
 
Peritoneal Lavage Exosomes Gene Signature in Gastric Cancer Peritoneal Carcinomatosis
Investigator
Maheswari Senthil, MD, Department of Surgery, UC Irvine School of Medicine
Gastric cancer is an aggressive cancer that often spreads to the lining of the abdominal cavity and is associated with a very high death rate. This problem disproportionately affects Latinx race/ethnic group. One of the major challenges with gastric cancer spread to abdominal cavity is lack of diagnostic studies that can accurately identify the problem and assess treatment response. We propose to study nanovesicles (exosomes) in the abdominal cavity fluid as a way to develop a diagnostic tool that can accurately identify cancer spread in the abdominal cavity and predict treatment response. We believe, study of nanovesicles will help develop a more accurate diagnostic tool and will greatly facilitate advancing treatment in patients with gastric cancer with intraabdominal spread.
 
Enhancing CAR T cell Activity by Eliminating Branched N-glycans
Supported by Team Answer for Cancer

Investigator
Michael Demetriou, MD, PhD, Departments of Neurology and Microbiology & Molecular Genetics, UC Irvine School of Medicine
Prognosis is abysmal for patients with advanced solid tumors and there is an urgent unmet need for novel mechanisms of action and additional paradigm shifting therapeutic options. Genetically engineering immune cells to bind and kill cancer cells is a highly potent way of treating liquid cancers, but has been unsuccessful in solid cancers due to lack of binding targets and immunosuppression. Here we propose to address both these roadblocks by genetically engineering an immune cell that 1) targets a novel sugar-antigen expressed in the vast majority of solid cancers and 2) is resistant to immunosuppression via alterations in complex sugar-chains.
 
Study the Role of Mutated NF2 in Neurofibromatosis Type 2 Cancer
Investigator
Wenqi Wang, PhD, Department of Developmental and Cell Biology, UC Irvine School of Biological Sciences
Neurofibromatosis type 2 is a childhood cancer with tumors developed in brain and throughout the nervous system. This cancer is an autosomal dominant genetic disorder and majorly caused by the NF2 gene mutation, which means that the child will inherit the cancer if just one parent’s NF2 gene has a mutation. In this application, we propose to investigate an oncogenic pathway that is activated by the mutated NF2 and also required for the mutated NF2-induced cancer development. We will investigate the underlying mechanism and determine the therapeutic potential by targeting this oncogenic pathway for treating the NF2 mutated neurofibromatosis type 2 cancer.
 
Early Detection and Diagnosis of DNA Repair Deficient Hereditary Cancers
Supported by Team Answer for Cancer

Investigator
Nicholas Pannunzio, PhD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Jennifer Valerin, MD, PhD, (Co-Principal Investigator), Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Hereditary cancer syndromes are thought to drive cancer in approximately 5% of cases. Patients carrying mutations are at high risk for the development of multiple tumors at an early age. Genetic counselors are in demand and limited testing may be performed due to availability or financial resource. Additionally, the impact of these syndromes is far wider due to the effect on family members who may not even have a cancer diagnosis and don't have access to testing.
 
Single Molecule Dissection of Cancer-Associated Kinase Mutants
Investigator
Gregory Weiss, PhD, Department of Chemistry, UC Irvine School of Physical Sciences
Enzymes drive cell growth and cell division, and all cancers prominently feature improper enzyme activity by a class of signal transmitting enzymes, termed kinases. Thus, understanding such proteins is critically important for the development of more effective anti-cancer therapeutics. This proposal simplifies and reinvents a nanometer-scale technology for directly observing and dissecting kinases while they catalyze chemical transformations at the heart of cancer formation. This research aims to reveal targets for the development of drugs and diagnostics with novel mechanisms and capabilities.
 
Enhancing the Efficacy of Radiation Therapy by Surgically Targeted Radiation-Sensitizer Loaded Hydrogels: Translation of in Vitro Results to a Post-Resection Rat Brain Tumor Model
Investigator
Henry Hirschberg, PhD, The Beckman Laser Institute, UC Irvine School of Medicine
This research project has as its aim to enhance the therapeutic effects of image guided radiation therapy in the treatment of primary brain cancer. A slow-release delivery system for compounds termed radiation sensitizers, known to enhance the effects of radiation therapy, will be implanted in the cavity formed after surgical removal of a major portion of the tumor. Enhancing the site-specific ability of radiation to selectively kill tumor cells, while spearing normal tissue, would result in a higher chance of cure and reduce unwanted treatment side effects. The development of the proposed therapeutic modality would potentially not only improve the prognosis of patients suffering from primary and metastatic brain tumors but would also be applicable to other forms of operable cancer, such as breast and lung.
 
Characterization of the Immune Response to Neoadjuvant Anti-PD-1 and -LAG3 therapy in Stage 3 Melanoma
Investigators
Francesco Marangoni, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Warren Chow, MD, (Co-Principal Investigator), Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Pre-operative and post-operative immunotherapy with a single immune-activating antibody is the new standard of care for patients with locally-advanced (lymph node positive) melanoma. The addition of a second, immune activating antibody has improved outcomes for patients with metastatic melanoma. We will test the use of two immune-activating anti-PD-1 and anti-LAG3 antibodies, AND increasing the number of doses pre-operatively to improve outcomes for patients with locally-advanced melanoma. In this Anti-Cancer Challenge proposal, we will characterize and quantify the immune response in the blood at landmark time points before treatment, and after pre-operative and post-operative immunotherapy.
 
Innate Immune Agonist Codrugs for Cancer Immunotherapy
Investigators
Thomas Burke, PhD, Department of Microbiology and Molecular Genetics, UC Irvine School of Medicine
Vy Dong, PhD, (Co-Principal Investigator), Department of Chemistry, UC Irvine School of Physical Sciences
We are developing a new class of small molecule anti-cancer drugs that could be used to treat many cancer indications. Our approach targets the innate immune system, and thus these drugs can synergize with existing immunotherapies that activate adaptive immunity, like checkpoint inhibitors. Our efforts will aid public health by advancing novel anti-cancer drugs towards the clinic, and if successful could lead to clinical trials.
 
Health Disparities and Early-Onset HER2+ Breast Cancer in Vietnamese Women
Investigators
Devon Lawson, PhD, Department of Physiology and Biophysics, UC Irvine School of Medicine
Kai Kessenbrock, PhD, (Co-Principal Investigator), Department of Biological Chemistry, UC Irvine School of Medicine
Erin Lin, MD, (Co-Principal Investigator), Department of Surgery, UC Irvine School of Medicine
Robert Edwards, MD, (Co-Principal Investigator), Department of Pathology, UC Irvine School of Medicine
This proposal aims to fill the research gap regarding mechanisms of breast cancer initiation in the Vietnamese community in our catchment area in Orange County. Studies from the California Cancer Registry reveal that Vietnamese women are disproportionately affected by aggressive HER2+ breast cancer compared to non-Hispanic White women. To investigate potential biological mechanisms underlying this heightened risk, our team will utilize single-cell and spatial technologies to analyze both normal and malignant tissues from Vietnamese patients and compare them to tissues from women representing other race/ethnic groups. Our research will not only addresses a critical gap in understanding breast cancer disparities but also offers potential for tailoring treatment strategies to Vietnamese women specifically in our catchment area in OC
 
Regulatory Effects of Xist on the Development of Female and Male Colorectal Cancer
Investigators
Mei Kong, PhD, Department of Molecular Biology and Biochemistry, UC Irvine School of Biological Sciences
Sha Sun, PhD, (Co-Principal Investigator), Department of Developmental & Cell Biology, UC Irvine School of Biological Sciences
The proposed approach of using transgenic mouse models will set an example to address specific factors contributing to sex differences in cancer development. In precision medicine, understanding the genetic and epigenetic basis for the difference in cancer incidence between men and women will lead to the development of drugs and prevention strategies that consider a patient’s gender. The proposed research could help improve individual health outcomes by providing deeper insights into living systems.

 

2023 TRACK 2: EARLY PHASE CLINICAL TRIALS

Phase IB, Open-Label Trial of Dual Cytotoxic and Immune-Stimulatory Gene Therapy in Combination with G-CSF for the Treatment of Resectable, Recurrent Glioblastoma (GBM)
Investigator
Daniela Bota, MD, PhD, Department of Neurology, UC Irvine School of Medicine
GBM is one of the hardest cancers to treat, with an average survival of 12-18 months. The patients receive surgery, radiation, and chemotherapy (temozolomide), but the tumors resume growth and progression after 7-9 months. There are no effective treatments for patients who experience tumor growth after the initial treatment. In California, about 1,700 people were diagnosed with GBM, and 1,200 succumbed to the disease in 2023. The GBM diagnosis is associated with severe neurological disability, reduced quality of life, and high levels of stress for the patients and their caregivers. The healthcare cost of treating one GBM patient is more than $450,000 and can reach $700,000. Finding a potential treatment for this deadly disease would benefit California patients, caregivers, and the state-supported healthcare system.
 
Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Breast Cancer Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial
Investigators
Alexandre Chan, PharmD, MPH, Department of Clinical Pharmacy Practice, UC Irvine School of Pharmacy & Pharmaceutical Sciences
Ritesh Parajuli, MD, (Co-Investigator) Division of Hematology Oncology, Department of Medicine, UC Irvine School of Medicine
Breast cancer is highly curable, yet up to 75% of breast cancer survivors in the community experience various levels of impaired cognition even many months after cancer free. Our clinical trial is evaluating a drug that may provide symptomatic relief to these survivors who are having difficulty incorporating back into the community, in view of their symptoms and reduced quality of life.
 
Epcoritamab Consolidation in Patients with Chronic Lymphocytic Leukemia Who Are in Remission on Continuous BTK Inhibitors
Supported by Team Answer for Cancer

Investigators
Catherine Coombs, MD, Department of Medicine, UC Irvine School of Medicine
Susan O’Brien, MD, (Co-Investigator) Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
The most prescribed agents for patients with chronic lymphocytic leukemia (CLL) are Bruton tyrosine kinase inhibitors (BTKi), which are used continuously. However, in surveys of CLL patients, the majority of patients express a preference for time-limited regimens, especially when considering the cost of continuous therapy. Cost can be financial but may also be related to a detriment in quality of life, as BTKi may cause chronic toxicities. As such, conversion from a continuous treat-to-progression approach for patients who are on BTKi to a time-limited approach would be of interest to many patients. As epcoritamab has exhibited impressive efficacy as a single agent, the addition of epcoritamab to patients who are in a clinical remission while on a BTKi would likely led to high proportion deep remissions that would then allow for a treatment-free remission.
 
Adjuvant Sacituzumab Govitecan plus Nivolumab in Patients with Muscle-Invasive Urothelial Carcinoma at High-Risk for Cancer Recurrence who are ctDNA positive
Investigator
Nataliya Mar, MD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
The prognosis of metastatic urothelial carcinoma of the bladder, ureter and kidney remains poor, with only 7.7% of patients being alive at 5 years from diagnosis. As such, better treatment options are needed to prevent development of cancer returning/relapsing following surgery aimed to cure localized urothelial cancer. This study aims to evaluate the effectiveness and safety of combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma and minimal residual disease as detected by positive ctDNA, who are at high risk of cancer recurrence post-curative intent surgery.
 

2022 Funded Research

2022 TRACK 1: PILOT PROJECTS

New Strategies to Overcome Therapeutic Resistance in Pancreatic Cancer
Investigators:
Aimee Edinger, PhD, VMD, Department of Developmental & Cell Biology, UCI School of Biological Sciences
Chris Halbrook, PhD (Co-Principal Investigator), Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
Pancreatic cancer is a dreaded diagnosis - most patients die within 5 years of learning they have the disease. Chemotherapy offers limited benefits, and new therapies that stimulate the body’s immune system to reject the tumor do not work well in pancreatic tumors. Our preliminary studies suggest that we have uncovered a new way that pancreatic cancers hide from the immune system. If we are correct, adding new drugs that have already been shown to be safe in humans to existing treatment regimens may help patients fight this terrible disease.
 
Optimizing the Impact of Social Media to Reduce Unmet Needs for Young Adult Cancer Survivors
Investigators:
Anamara Ritt-Olson, PhD, Department of Health, Society, and Behavior, UCI Program in Public Health
Joel Milam, PhD, (Co-Investigator), Department of Epidemiology and Biostatistics, UCI Program in Public Health
Candice Odgers, PhD, (Co-Investigator), Department of Psychological Science, UCI School of Social Ecology
Young adult survivors of cancer commonly experience unmet information needs concerning disease outcomes, ways to protect their mental and physical health, and ways to address daily struggles. There are locally available resources in Orange County that can help address many of these needs, but they remain underutilized. We will co-create with cancer community members a moderated Instagram site where survivors can share reviews about local resources with each other. We will test ways to increase motivation to review resources, ways to engage with the site, and will explore if reviews help survivors engage with local resources.
 
Using Single Cell Transcriptomics to Elucidate Fundamental Mechanisms of Cancer Surveillance
Investigator:
Arthur Lander, MD, PhD, Department of Developmental and Cell Biology, UCI School of Biological Sciences
Exciting breakthroughs in cancer treatment have recently come from stimulating the immune system, but treatments are successful only in some cases, and efforts to do better are hampered by a lack of understanding of how the immune system recognizes cancer cells and targets them for attack—a process called “immune surveillance”. Studies in animal models increasingly suggest that immune cells called macrophages scan the body specifically looking for patterns of growth that are not uniform, and selectively eliminating cells not growing like their neighbors. Using one of the simplest animal systems in which this process occurs—the fruit fly—we seek to identify the signals that recruit macrophages to such sites of “cell misbehavior”, so that we may translate a better understanding of immune surveillance into better cancer prevention and treatment.
 
Exploiting USP7 Inhibitors as a Therapeutic Approach In Osteosarcoma
Investigators:
Claudia Benavente, PhD, Department of Pharmaceutical Sciences, UCI School of Pharmacy and Pharmaceutical Sciences
Elyssa Rubin, MD, (Co-Principal Investigator), Bone and Soft Tissue Tumor Program, CHOC
Osteosarcoma is the most common primary bone cancer and occurs in adolescents and young adults. Metastasis remains the most important fatal complication in osteosarcoma. Thus, there is a pressing clinical need to develop new therapeutic strategies targeting the factors responsible for metastasis. We will establish the feasibility of exploiting novel developed compounds to prevent osteosarcoma metastasis. Further, we will work with Children’s Hospital of Orange County (CHOC) to develop a patient-derived xenograft tumor bank for OS which could be used to run future pre-clinical trials for novel compounds.
 
Connecting Mevalonate Pathway with Oncogene Transcriptional Networks in Leukemia
Investigator:
David Fruman, PhD, Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
Acute myeloid leukemia (AML) is a deadly blood cancer, and most patients respond poorly to current treatments. Our laboratory has discovered that widely used cardiovascular drugs called statins have potential to improve AML disease control by one of the current AML therapies. The goal of this project is to strengthen our understanding of how statins turn off survival signals in AML cells. Our ultimate goal is to translate this knowledge into new therapies that can improve the lives of AML patients.
 
Targeting Breast Cancer Metastasis with Natural Killer cells
Investigators:
Devon Lawson, PhD, Department of Physiology and Biophysics, UCI School of Medicine
Matthew Marsden, PhD (Co-Principal Investigator), Department of Microbiology and Molecular Genetics, UCI School of Medicine
The body’s immune system is a key player in cancer prevention. Previous work has shown that cancer cells can develop many different ways to evade the body’s immune system in order to grow and produce a tumor. One specific class of immune cells known as Natural Killer (NK) cells have an innate and potent ability to target and destroy cancer cells. In recent work, we found that cancer cells develop ways to inhibit this function of NK cells in order to metastasize and spread throughout the body. In this pilot project, we will use cutting-edge single cell genomics methods to determine the exact mechanism for how metastatic cells suppress NK cells. The goal of this project will be to use this knowledge to develop new ways to revive and boost NK cell function to target and destroy metastasizing cells. 

Elucidating the Role of Gut Microbiome in Tamoxifen Pharmacokinetics
Investigators:
Elizabeth Bess, PhD, Department of Chemistry, UCI School of Physical Sciences
Cholsoon Jang, PhD (Co-Principal Investigator), Department of Biological Chemistry, UCI School of Medicine
Katrine Whiteson, PhD (Co-Investigator), Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
Although tamoxifen is used in nearly half a million people in the U.S. each year to prevent breast cancer recurrence, this drug is effective in only 50% of patients. Accurate prediction of which patients will receive the beneficial effects of tamoxifen is still lacking. Our initial studies show that a key to solving this mystery is likely in the human gut microbiome, which is markedly different between individuals and known to affect various drug effects. In this project, we will identify how gut bacteria control tamoxifen’s effectiveness, laying the foundation to predict a patient’s potential to benefit from tamoxifen therapy.
 
Interventions to Improve Lung Cancer Screening
Investigators:
Gelareh Sadigh, MD, Department of Radiological Sciences, UCI School of Medicine
Hari Keshava, MD, (Co-Investigator), Department of Surgery, UCI School of Medicine
Sunmin Lee, ScD, (Co-Investigator), Department of Medicine-Hematology/Oncology, UCI School of Medicine
Tan Nguyen, MD, (Co-Investigator), Department of Family Medicine, UCI School of Medicine
Michael Hoyt, PhD, (Co-Investigator), Department of Population Health and Disease Prevention, UCI Program in Public Health
Adherence to lung cancer screening remains low with multiple contributing patient- and provider-level barriers. Effective interventions to address such barriers among diverse populations and improve lung cancer screening adherence are lacking. Our study will assess perceptions and barriers towards lung cancer screening among a diverse racial/ethnic population-some of whom receiving care in community health centers- and their providers. We will test feasibility of a multilevel intervention addressing patient and providers’ barriers and use a mixed method approach to further refine our intervention for future larger effectiveness trials.
 
Quadruple Targeting Fabs (QT-Fab) for Pancreatic Cancer Treatment: Bispecific Fabs Conjugated to Two Anti-Cancer Therapeutics
Investigator:
Gregory Weiss, PhD, Department of Chemistry, UCI School of Physical Sciences
Despite many years of research, pancreatic cancer remains the third deadliest cancer. This proposal carefully considers what makes such cancers exceptionally resistant to conventional anti-cancer approaches and then uses new chemistry discovered in the PI’s lab to address prior limitations in pancreatic cancer treatment. Specifically, the proposal describes a new approach to the discovery of small antibodies requiring two halves to bind to tumor cells, insuring better specificity for only cancer cells, and then delivering two different cancer-specific drugs.
 
The Role of Vitamin D on Mast Cell Activation and Neuroinflammation in Paclitaxel-Induced Peripheral Neuropathy
Investigator:
Hyun Don Yun, MD, Department of Medicine-Hematology/Oncology, UCI School of Medicine/Long Beach VA
Breast cancer is the most common type of female cancer, but breast cancer treatment can cause severe nerve damages causing numbness, tingling and pain with a poor quality of life of the affected patients. The clinical strategies for the treatment or prevention of chemotherapy-related nerve damage are not well established. Often, the nerve damage related to chemotherapy is worsened by certain immune cells. Our research study will test the treatment effect of vitamin D in reducing the nerve damage caused by chemotherapy using human nerve and immune cells in laboratory.
 
Stress & Coping in Asian Americans with Advanced/Metastatic Cancer
Investigators:
Jacqueline Kim, PhD, Department of Medicine-Hematology/Oncology, UCI School of Medicine
Sunmin Lee, ScD (Co-Investigator), Department of Medicine-Hematology/Oncology, UCI School of Medicine
The social contexts and risk/resilience factors influencing the experiences of Asian Americans with advanced/metastatic cancer need to be better understood to improve quality of life. This pilot study will support larger funding allowing for deeper insights into how ethnoracial minority/immigrant experiences shape living with advanced/metastatic cancer. The long-term goal of this research is to suggest: 1) guidelines for screening of important social circumstances in cancer care, 2) next steps for psychosocial/behavioral interventions to buffer ethnoracial minority/immigrant-related stress, and 3) relevant biomarkers for improving patient-reported outcomes.
 
Evaluating BRCA-Mediated Ovarian Tumorigenesis and Metastasis Through Spatial Mapping and RNA-Sequencing at the Single-Cell Level
Investigators:
Kai Kessenbrock, PhD, Department of Biological Chemistry, UCI School of Medicine
Alyssa Bujnak, MD, (Co-Principal Investigator), Department of Obstetrics and Gynecology, UCI School of Medicine
Jill Tseng, MD, (Co-Principal Investigator), Department of Obstetrics and Gynecology, UCI School of Medicine
We seek to understand how ovarian tumors form and progress through studying the ovarian tissue and ovarian tumors of a group of patients with a mutation called BRCA, that are prone to developing ovarian cancer. We will use cutting edge technology allowing us to identify how individual cells in the ovary tissue and tumors are behaving and how they interact with neighbor cells. We theorize that certain types of cells in the ovaries of the patients with BRCA mutations are acting abnormally, causing other cells in the ovary to turn into cancer. This information may promote the development of methods to detect ovarian cancer earlier, and to create new treatments that will improve the lifespan of women with ovarian cancer.
 
"Image-guided Precision Radiotherapy" Team Science Seed Grant
Investigators:
Liangzhong Xiang, PhD, Department of Radiological Sciences, UCI School of Medicine
Charles Limoli, PhD, (Co-Principal Investigator), Department of Radiation Oncology, UCI School of Medicine
Zhongping Chen, PhD, (Co-Principal Investigator), Department of Biomedical Engineering, UCI School of Engineering
Thomas Milner, PhD, (Co-Principal Investigator), Department of Surgery, UCI School of Medicine
Vahid Yaghmai, MD, (Co-Principal Investigator), Department of Radiological Sciences, UCI School of Medicine
When treating cancer with radiation therapy, imaging is crucial to help plan and deliver the treatment effectively. However, with the emergence of a new type of radiation therapy called FLASH, which has potential benefits but also poses risks, new imaging techniques are needed to account for daily changes during treatment. Researchers are working on a new imaging modality called radiation-induced acoustic imaging, which will provide real-time 3D dose verification for FLASH therapy. This new technology will help ensure that the treatment is delivered precisely and accurately to the tumor and healthy tissues. This breakthrough can lead to a paradigm shift in using FLASH-RT for cancer treatment, which can benefit patients who may suffer from radiation-induced toxicities.
 
Multiomic Study of Merkel Cell Carcinoma Heterogeneity at the Single Cell Level
Investigator:
Ling Gao, MD, PhD, Department of Dermatology, UCI School of Medicine/Long Beach VA
MCC is far deadlier than melanoma, especially if not detected at early stage, with no effective targeted therapy and no definitive treatment for patients ineligible or resistant to immunotherapy. The increasing incidence of MCC is creating a growing impact on public health, particularly for Caucasian males between the ages of 60 and 85, who comprise nearly two-thirds of MCC patients and are well-represented within the Veteran population. Since the first FDA approval of immune checkpoint inhibitors, we still treat all MCC patients as one entity and more than half of metastatic MCC patients still succumb to their diseases, with median progression survival of only 2.7 months. This work will optimize the workflow in delineating MCC heterogeneity and fill in the clinical gaps.
 
Neuroblastoma with Resistance to Chemotherapy: A Therapeutic Strategy Based on Mitochondrial-Mediated Ferroptosis
Investigator:
M. Cristina Kenney, MD, PhD, Department of Ophthalmology, UCI School of Medicine
MYCN-amplified (MYCN-amp) neuroblastoma (NB) frequently spreads, is resistant to standard treatment and accounts for a significant portion of pediatric cancer fatalities. Ferroptosis is regulated cell death in which reactive oxygen species (ROS) are created through an iron-dependent process. We hypothesize that increasing levels of mitochondrial-mediated ferroptosis will inhibit the inflammation-related cGAS-STING pathway and cause the high-risk NB cells to lose their chemo-resistant property. We will investigate - (i) whether chemotherapy-resistant NB is sensitive to mitochondrial-dependent ferroptosis, and (ii) if ferroptosis plays a role in aggressive NB progression.
 
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
Investigator:
Mahtab Jafari, PharmD, Department of Pharmaceutical Sciences, UCI School of Pharmacy and Pharmaceutical Sciences
The personality and disposition of a patient may be a key factor that determines whether or not they follow the prescribed medication plan that has been laid out by their care provider. In turn, using treatment education strategies that are intentionally tailored to align with a patient’s personality may be a critical next step that healthcare providers can take to improve adherence. While some studies of other chronic diseases have found links between patients’ personalities and adherence, there is yet to be a study that specifically examines the personality of patients with chronic myeloid leukemia (CML) and how this might affect adherence to oral therapy with tyrosine kinase inhibitors such as imatinib. In this study, we will use a validated personality assessment and targeted interviews to gather data on 75 patients with CML in Orange County, which we will use to analyze the impact that patient personality might have on TKI adherence for those diagnosed with CML. Our findings will be useful in the design of future studies that utilize health coaches to improve the adherence of patients with CML to their therapy through an individualized program that takes personality into account.
 
Glucocorticoid Pre-Treatment of Mouse And Human Donor Grafts for Prevention of Graft-Versus-Host Disease While Maintaining Graft-Versus-Leukemia Response in Allogeneic Hematopoietic Cell Transplantation
Investigator:
Matthew Inlay, PhD, Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
Hematopoietic cell transplantation (HCT), also known as blood and marrow transplantation (BMT), is a potentially curative treatment for diseases of the blood, including blood cancers, where a patient’s diseased blood system can be completely replaced with that from a healthy donor. However, many risks remain, such as graft-versus-host disease (GvHD), caused when donor immune cells attack patient tissues, causing systemic inflammation, organ damage, and possibly death. The research in this proposal explores a potential treatment to prevent GvHD by manipulating the immune cells in the donor graft with glucocorticoids prior to transplantation. If successful, this research could improve the safety and efficacy of HCT and allow expansion of the pool of available donors for a patient to include haploidentical matches, which includes all parents and half of siblings.
 
Cell Therapy for Muscle Atrophy Following Irradiation in Rhabdomyosarcoma
Investigator:
Michael Hicks, PhD, Department of Physiology and Biophysics, UCI School of Medicine
Most cancer research focuses on new treatments and diagnostics such as through sequencing, yet few studies investigate how to improve quality of life for cancer survivors following current standards of care. Sarcomas are a group of deadly cancers that require aggressive radiotherapy to ablate the tumor; however, radiation often results in permanent dysfunction of nearby healthy tissues and long-term patient disability at the irradiation site. This research seeks to reconstruct new skeletal muscle following cancer radiotherapy using muscle stem cell therapy approaches.
 
Translating Goal-Focused Emotion Regulation Therapy to Young Adults Across Cancer Diagnoses
Investigators:
Michael Hoyt, PhD, Department of Population Health and Disease Prevention, UCI Program in Public Health
Jamie Frediani, MD, (Co-Principal Investigator), Adolescent and Young Adult Oncology Program, CHOC
Baolin Wu, PhD, (Co-Principal Investigator), Department of Epidemiology and Biostatistics, UCI Program in Public Health
Michelle Fortier, PhD, (Co-Principal Investigator), UCI Sue & Bill Gross School of Nursing
Establishing the ability to test the GET intervention in a broader population of young adult survivors expands the ability to meet the needs of a larger portion of our catchment area populations. The current study also increases the opportunities to partner with CHOC in the current project and the future clinical trial. This project will progress this work along the translational spectrum and is a necessary precursor to testing efficacy in a more representative population.
 
New Machine Learning Methods to Identify Metabolomic and Genomic Biomarkers for Colorectal Cancer
Investigators:
Min Zhang, MD, PhD, Department of Epidemiology and Biostatistics, UCI Program in Public Health
Mei Kong, PhD (Co-Principal Investigator), Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
The profiling of intermediary metabolites is emerging as an important platform for understanding the mechanisms underlying common chronic diseases, such as diabetes and cancer. Based on our successful identification of blood metabolomic biomarkers for colorectal polyps and the estimated genetic predisposition to colorectal cancer, we propose to identify metabolite and genomic biomarkers in animal models and human populations using our newly developed machine learning methods. The identified integrated metabolomic and genomic biomarkers will facilitate the early detection of colorectal cancer and improve disease risk prediction.
 
Quantifying Transarterial Embolization Outcome Using Optical Molecular Imaging
Investigators:
Nadine Abi-Jaoudeh, MD, Department of Radiological Sciences, UCI School of Medicine
Gultekin Gulsen, PhD, (Co-Investigator), Department of Radiological Sciences, UCI School of Medicine
Farouk Nouizi, PhD, (Co-Investigator), Department of Radiological Sciences, UCI School of Medicine
Assumptions that vessel occlusion of liver tumors will lead to ischemia have led to clinically mediocre patient outcomes. Understanding the consequences of transarterial embolization on tumor oxygenation is paramount. We propose to develop a dedicated CT-guided optical molecular imaging system to directly measure the changes in oxygenation levels and perfusion globally throughout the tumor before, during and after embolization in VX2 rabbit tumor model.
 
Flexible Fiber-Based Laser Micro-Biopsy Platform for Minimally-Invasive Tissue Collection and Processing During Cancer Surgery
Investigators:
Oliver Eng, MD, Department of Surgery, UCI School of Medicine
Thomas Milner, PhD (Co-Principal Investigator), Department of Surgery, UCI School of Medicine
Ryan O'Connell, MD (Co-Principal Investigator), Department of Pathology, UCI School of Medicine
Nitesh Katta, PhD (Co-Investigator), Beckman Laser Institute, University of California, Irvine
Colon cancer is one of the most common cancers worldwide and, in particular, accounts for a significant portion of patients who present to UCI for treatment. The management of colon cancer when it has spread or metastasized often requires biopsies to obtain tissue, which helps guide individualized treatment. Biopsy techniques and tissue processing have limitations and can be improved upon; therefore, we propose a novel platform which could potentially affect millions of patients annually.
 
Innate Immune Agonist Codrugs for Cancer Immunotherapy
Investigators:
Thomas Burke, PhD, Department of Microbiology and Molecular Genetics, UCI School of Medicine
Vy Maria Dong, PhD (Co-Principal Investigator), Department of Chemistry, UCI School of Physical Sciences
The innate immune system fights against infection by detecting pathogens and eliciting potent inflammatory responses. We propose to repurpose this signaling for cancer immunotherapy by synthesizing new small molecules that target multiple arms of the innate immunity to elicit synergistic inflammatory responses and to test these drugs in melanoma models in mice. These molecules could potentially be used to treat a variety of cancer indications and would work in combination with existing immunotherapies that activate adaptive immunity. These efforts will aid public health by advancing anti-cancer drugs towards the clinic and by establishing novel strategies for activating the immune system to fight cancer.
 
Is There a Link Between Prostate Cancer and HPV?
Investigators:
Wendy Cozen, DO, MPH, Department of Medicine-Hematology/Oncology, UCI School of Medicine
Arash Rezazadeh Kalebasty, MD (Co-Principal Investigator), Department of Medicine-Hematology/Oncology, UCI School of Medicine

Public health officials estimate 380 new cases of prostate cancer among Orange County men each year, with 22% of these diagnosed at late stage. Because of changes in screening, there has been an overall increase in late-stage prostate cancer. Unlike many cancers, there are no known behavior or other modifications shown to prevent prostate cancer (most of the known risk factors like, age, race/ethnicity and genetic factors, cannot be changed). There have been some reports that human papillomavirus (HPV) may be a risk factor for prostate cancer but there is no consensus. We are proposing a well-designed study of twins comparing a prostate cancer patient to their twin who never developed prostate cancer (the perfect control). We will measure previous exposure to HPV and two other infectious organisms by measuring antibodies which are unaffected by the cancer. If we can show a link between HPV and prostate cancer, it will provide a rationale to vaccinate boys with Gardasil, the HPV vaccine, for future prevention in Orange County, and to measure HPV antibodies in older men to justify continued screening with the prostate specific antigen test (PSA). Thus, the results would have a high impact on men in Orange County.

2022 TRACK 2: EARLY PHASE CLINICAL TRIALS

A Phase II Study of Adding Pitavastatin to Venetoclax-Based Therapy in Acute Myeloid Leukemia (AML)
Investigators:
Elizabeth Brem, MD, Department of Medicine-Hematology/Oncology, UCI School of Medicine
David Fruman, PhD, (Co-Principal Investigator), Department of Molecular Biology and Biochemistry, UCI School of Biological Sciences
Some cancer cells take advantage of a protein called BCL2 to help them stay alive, and venetoclax (VEN) is an oral medicine that inhibits BCL2 to help kill cancer cells. Statins are medicines taken very commonly for the treatment of high cholesterol. Experiments done in the laboratory with cell lines and cells taken from people with leukemia suggest that statins may help VEN work better. In a phase 1 study, we have not seen any worse or different side effects when people took a statin called pitavastatin with VEN therapy for leukemia. Here, we propose a phase 2 study to help better understand if adding pitavastatin helps improve responses to VEN therapy for acute myeloid leukemia.
 
A Phase 1b Feasibility Trial of Response Adapted Neoadjuvant Therapy in Gastric Cancer (RANT-GC)
Investigator:
Farshid Dayyani, MD, PhD, Department of Medicine-Hematology/Oncology, UCI School of Medicine
Gastric cancer is the third leading cause of death from cancer globally, and despite the best current ‘one size fits all’ treatment of peri-operative chemotherapy and surgery, less than 50% of patients can be expected to be cured even in early-stage cancer. Importantly, only 50% of the patients can tolerate the required post-operative course of chemotherapy (e.g., due to slow recovery after surgery), which potentially contributes to worse outcomes. This proposal will use cutting edge molecular technology (i.e., tumor specific circulating tumor DNA in the plasma) to inform and personalize the pre-surgical treatment regimen used based on the individual tumor’s response, and hence maximize the upfront tumor shrinkage prior to curative intent surgery. Since all treatment is given before surgery, we also hypothesize that the patients will tolerate more of the expected chemotherapy those, further helping with eradicating the cancer completely.
 
A Pilot Study to Assess The Diversity Of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects
Investigator:
Misako Nagasaka, MD, PhD, Department of Medicine-Hematology/Oncology, UCI School of Medicine
Approximately 40 trillion microbial cells are thought to live on and inside the human body and the largest number of microbial species reside in the gastrointestinal tract and are often referred to as “the gut microbiome.” In recent years, the imbalance of the gut microbiome, or dysbiosis, has been shown to be associated with different diseases including cancer. Constantly being exposed to numerous potential pathogens of the outer world, it is not surprising that the gut microbiome plays a critical role in the host immune response.
This pilot study aims to describe the effects of gut microbiome in lung cancer patients, particularly on how they may impact different treatment (immunotherapy, chemotherapy, and targeted therapy) by collecting and analyzing stool and saliva samples before treatment and at the time of their first imaging for treatment response. We expect high accrual of those considered to be of underrepresented minority (women, racial ethnic minorities) as targetable mutations have a higher prevalence in them. As such, this study is consistent with the CFCCC’s mission of inclusion.
 
Phase I Clinical Trial Using Donor-derived BK Virus-specific T-cells (BK-VSTs) for Patients Who Develop Hemorrhagic Cystitis after Allogeneic Stem Cell Transplantation (PIVOT)
Investigators:
Stefan Ciurea, MD, Department of Medicine-Hematology/Oncology, UCI School of Medicine
Catherine M. Bollard, MD (CNH), (Co-Principal Investigator), Center for Cancer and Immunology Research, Children’s National Hospital
Michael Daniel Keller, MD, (Co-Principal Investigator), Division of Allergy and Immunology Research, Children’s National Medical Center
Patrick J. Hanley, PhD, (Co-Principal Investigator), Cellular Therapy Program, Children’s National Medical Center
Piyanuch Kongtim, MD, (Co-Principal Investigator), Department of Medicine-Hematology/Oncology, UCI School of Medicine
Rishikesh Shahajirao Chavan, MD, (Co-Principal Investigator), Blood and Marrow Transplant Program, CHOC
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a curative treatment option for patients with high-risk or advanced hematological malignancies. BK virus (BKV) infection after AHSCT has been associated with significant morbidity, prolonged hospitalization, and increased mortality in AHSCT recipients and can cause varying degrees of hemorrhagic cystitis (HC), obstruction of the urinary tract, kidney injury and nephritis. Treatment of HC is largely supportive with no effective drug therapy currently exists. Administration of third-party BK viral specific T cells (BK-VSTs) has been shown to effectively decrease BK uremia and improve symptoms of BK associated hemorrhagic cystitis (HC). However, the use of third-party BK-VSTs could increase the risk of graft versus host disease (GVHD) and decrease persistence of the T cells. In this study, we aim to determine the safety, feasibility as well as efficacy of donor-derived BK-VSTs for AHSCT recipients with BK viruria/viremia to prevent severe HC and decrease the risk of GVHD associated with third-party BK-VSTs.

 

2021 Funded Research

2021 TRACK 1: PILOT PROJECTS 

Effects of Dietary Methionine Restriction on Splicing in Tumors 
Investigator:
Peter Kaiser, PhD,
Department of Biological Chemistry, UC Irvine School of Medicine
Immune checkpoint inhibitors are some of the most promising emerging therapies for cancers. Unfortunately, due to insufficient immunogenicity of some tumors only a fraction of cancers responds to current therapies. This project tries to increase tumor immunogenicity through specific diets that increase production of aberrant proteins in tumors to activate the anti-tumor immune response.

Defining Genomic Instability in Early Onset Colorectal Cancer in Us-Born Hispanics 
Investigator:
Nicholas Pannunzio, PhD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine

Colorectal cancer (CRC) is the third most diagnosed cancer in the United States. Though CRC cases in older adults have decreased, the incidence of CRC in young adults, ages 15-39, is on an alarming rise especially in Hispanics. The cause of this rise in young adult CRC cases is unknown, but is linked to environmental and dietary factors, which are known to disrupt the circadian clock that controls sleep cycles, diet, and metabolism. The goal of this proposal is to interrogate the role of the circadian clock in CRC and to define how disruption of circadian rhythms impacts young adult CRC, specifically in Hispanics.

Identifying Approaches to Effectively Target Metastatic Pancreatic Cancer
Investigator:
Christopher Halbrook, PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
Pancreatic cancer is a devastating digestive disease. Most patients are diagnosed with metastatic disease, and the few who qualify for removal of the primary lesion typically experience recurrence in secondary sites. As a result, nearly all patients die with metastatic disease. The site of pancreatic cancer metastasis is the liver, and research contained within this proposal will provide new insights into the effectiveness of methods to harness the immune system to target liver metastatic lesions.

Understanding and Addressing Cancer Survivorship Needs for Filipino-Americans in Los Angeles and Orange Counties
Investigator:
Sora Tanjasiri, DrPH, Department of Epidemiology and Biostatistics, UC Irvine Joe C. Wen School of Population & Public Health
Research aimed at understanding how social support and quality of life impacts the physical and mental health of cancer survivors have primarily focused on those affected by breast cancer, and only a subset investigated certain Asian American subpopulations. Filipino Americans account for the third-largest Asian American subgroup in the U.S., but only a limited number of studies, if any, have explored factors that affect the health-related quality of life and the long-term health care needs of Filipino American cancer survivors. This pilot study will use interviews with Filipino American cancer survivors and leaders in the community to explore the cancer-specific treatment and survivorship needs of Filipino Americans in Southern California and will contribute to the limited literature that focus on the unique unmet needs and psychosocial preferences of this understudied population. Findings will be used to develop supportive care interventions that improve quality of life factors for Filipino American cancer survivors.

Identifying Early Diagnosis Markers and Therapeutic Targets of Kidney Tumors in Young Tsc Patients
Investigator:
Gina Lee, PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
The kidney is an essential organ that eliminates harmful wastes from the blood into the urine and reabsorbs important nutrients. The tumor formation in the kidney, therefore, affects not only kidney function but also damages all other critical organs, causing lethal consequences. Using our state-of-the-art tissue surgery and chemistry techniques, we will determine how tumor-bearing kidneys affect kidney function and the whole body. We will also identify potential blood markers for early detection of kidney tumors by analyzing numerous patient samples obtained from the non-profit kidney tumor research foundation and UC Irvine’s cancer center. Our studies will reveal clinically important information about kidney tumors to facilitate the development of new drugs and diagnostic tools.

Functional Characterization of the Hippo Pathway in Cancer
Investigator:
Wenqi Wang, PhD, Department of Developmental and Cell Biology, UC Irvine School of Biological Sciences
The Hippo pathway has been established as a tumor suppressor pathway, whose deficiency is frequently observed in human cancers. In this proposal, we will focus on the Hippo pathway mutations identified in human cancers and investigate their effects on Hippo signaling. Completion of this proposed study will enrich our understanding of the Hippo pathway in human cancer development and allow us to reveal novel regulation and function for this key signaling pathway.

Vascularized Microtumor as a Drug Testing Platform for Peritoneal Carcinomatosis

Investigator:
Maheswari Senthil, MD, Department of Surgery, UC Irvine School of Medicine
Peritoneal Carcinomatosis is a form of cancer in which a tumor growing in organs like colon, rectum, stomach, appendix etc. spreads to the lining of the abdomen, namely the peritoneum. The treatment of PC is challenging, as standard-of-care cancer treatments are ineffective and are not customized to match the tumor behavior and biology. Hence, new treatment combinations are necessary to improve survival in PC, however progress in this area has been impeded by lack of pre-clinical tumor models that closely mimic the behavior of tumors in humans. We have extensive experience in creating vascularized microtumors and propose to develop a PC-specific version that is suitable to study the mechanisms of PC and assess response to various treatment combinations.


Elucidating Epigenetic and Metabolic Mechanisms Underlying Sex Differences in Cancer Development
Mei Kong, PhD, Department of Molecular Biology and Biochemistry, UC Irvine Charlie Dunlop School of Biological Sciences
According to American Cancer Society, cancer will affect 1 in 2 men and 1 in 3 women in their lifetime in US. Thus, sex differences in cancer incidence are apparent but remain poorly understood. Identifying specific genetic factors contributing to the differences in cancer incidence between men and women will eventually help drug development and prevention strategies that take a patient’s sex into consideration. This proposal aims to define the roles of a sex-chromosome associated gene in directly affecting cancer development and aggressiveness in male and female cells.

2021 TRACK 2: EARLY PHASE CLINICAL TRIALS

An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms
Investigator:
Angela Fleischman, MD, PhD,  Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
Myeloproliferative Neoplasm (MPN) is a chronic blood cancer characterized by uncontrolled production of blood cells. MPN patients have an increased risk of blood clots, accordingly treatment for this disease focuses on reduction of blood clotting risk. MPN patients have chronic inflammation which is responsible for the debilitating symptoms such as fatigue, headache, and severe itching that MPN patients suffer from. Although patients with early stage MPN can expect a relatively normal lifespan the disease can progress to myelofibrosis which is a bone marrow failure state, or acute leukemia which has a dismal prognosis. There are currently no treatments which prevent progression or cure MPN besides bone marrow transplant. We have recently found that the anti-oxidant supplement N-Acetylcysteine (N-AC) protects an animal model of MPN from blood clots. Moreover, we have found that N-AC blocks the production of inflammatory proteins by immune cells from both normal controls and MPN patients. These findings suggest that N-AC could have multiple benefits in
MPN patients, including reduction in blood clots, reduction in inflammation, and improvement in symptoms. We will now test the impact of N-AC on symptom burden, inflammatory protein levels, and markers of blood clots in a group of MPN patients. Moreover, it is possible that long-term treatment with N-AC could prevent progression of MPN through its anti-inflammatory or antioxidant effects. We anticipate that this initial clinical trial will lead to much larger studies that could establish N-AC as an easily accessible, low risk, low cost therapy in patients with MPN.


Electroacupuncture for the Management of Cancer-Related Cognitive Impairment in Adolescent and Young Adults — a Pilot Clinical Trial
Investigator:
Alexandre Chan, PharmD, MPH, Department of Clinical Pharmacy Practice, UC Irvine School of Pharmacy & Pharmaceutical Sciences
Adolescent and young adult (AYA) cancer survivors often experience cancer-related cognitive impairment (CRCI) which can lead to functional impairment at great economic, emotional, and social cost. Effective treatments are currently lacking for managing CRCI, and we aim to investigate the efficacy of electroacupuncture (EA) as a rehabilitation strategy to improve cognitive function and quality of life in AYA cancer survivors. The long-term goal is to optimize EA as an evidence-based integrative health treatment modality in managing AYA cancer survivors’ well-being.

 
A Feasibility Study for Application of AI to the Study of Integrative Oncology
Investigator:
Edward Nelson, MD, Division of Hematology/Oncology, Department of Medicine, UC Irvine School of Medicine
The diagnosis of cancer is frightening, disruptive, and fraught with symptoms and side effects and many patients with cancer, 10% to >75% in the literature, seek out and use complimentary and/or alternative medicine (CAM) modalities. Essentially all individual cancer practitioners have patients who have benefited from one or more CAM modalities. Traditional or allopathic medicine is diagnosis and specific symptom driven; whereas, CAM is viewed as being more holistic and CAM providers often “prescribe” multiple modalities for a patient. The multimodality approach of CAM along with the difficulties in establishing valid controls and identifying patients likely to benefit from a given modality has led to the study of CAM being insufficiently rigorous to result in adoption of CAM by mainstream medicine. With our College of Heath Sciences focus on Integrative Health, we propose a feasibility study to utilize artificial intelligence (machine learning) to be able to handle the multiple data streams that will be necessary to overcome the above major challenges in studying CAM, to provide an infrastructure for rigorous research into CAM modalities, to identify where and for whom these modalities should be recommended.

 

2020 Funded Research

2020 TRACK 1: PILOT PROJECTS 

The Role of Alternative Pre-mRNA Processing in Colon Cancer
Supported by the Goon Family
Investigators:
Klemens Hertel, PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
Marian Waterman, PhD, Department of Microbiology & Molecular Genetics, UC Irvine School of Medicine
Alternative pre-mRNA processing is a hallmark of many colon cancer genes, suggesting that aberrant pre-mRNA processing may contribute to the formation of tumors. This study proposes to determine if defects in alternative pre-mRNA processing contribute to the origin of colorectal cancer. The information obtained from this study will enable a more in-depth analysis identifying alternative processing signatures that promote tumor growth and progression. Trial results are likely to provide novel screening, outcome prediction and therapeutic possibilities.

Overcoming Barriers to Health-Information Seeking Behavior and Potential for Technology for Childhood Cancer Survivors (CCS)
Investigators:
Gillian Hayes, PhD, Department of Informatics, UC Irvine Donald Bren School of Information & Computer Sciences
Joel Milam, PhD, Department of Epidemiology and Biostatistics, UC Irvine Joe C. Wen School of Population & Public Health
Anamara Ritt-Olson, PhD, Department of Health, Society, and Behavior, UC Irvine Joe C. Wen School of Population & Public Health
Lilibeth Torno, MD, Pediatric Oncology, CHOC
Carol Lin, MD, Pediatric Oncology, CHOC
Christine Yun, MSN, PNP, CPON, Oncology, CHOC
The purpose of this study is to better understand how to maintain the health of adolescent and young adult (AYA) survivors of childhood cancer. The study will help us track the well-being and health of AYA survivors and understand how they seek needed care after completing cancer treatment. There are three main goals for this study: (1) to interview scientists, researchers, cancer advocates, patients and family members, and cancer care providers about the unique needs of AYA survivors; (2) to use those interviews to identify barriers that affect AYA childhood cancer survivors’ connection to chronic after-cancer care; and (3) to run a series of workshops to design technology to help AYA cancer survivors stay healthy.

 
Mechanisms of Local Treg Expansion in Melanoma Following PD-1 Blockade
Supported by Team Grandma Marcia
Investigators:
Francesco Marangoni, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Maki Yamamoto, MD, Department of Surgery, UC Irvine School of Medicine
Michael Cahalan, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Melanoma is one of the most common types of cancer in Orange County, yet 50% of patients with metastases do not respond to state-of-the-art checkpoint blockade immunotherapy and succumb to the disease. We studied the reasons for therapeutic failure and discovered that checkpoint blockade immunotherapy not only increases the immune response against melanoma, but also enhances the function of other components of the immune system, the so-called T regulatory (Treg) cells, which prevent immune responses from becoming too vigorous. We propose to study the mechanisms that lead to the expansion of Treg cells in melanoma in mice and humans after the administration of checkpoint inhibitors. This investigation will pave the way to more effective forms of melanoma immunotherapy.

Human Lymphoma Organoids as a Screening Platform for Drug Discovery and Precision Medicine in Non-Hodgkin Lymphoma
Investigators:
Lisa Wagar, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
Ash Alizadeh, MD, PhD, Department of Medicine—Oncology, Stanford University
Jenna Kastenschmidt, PhD, Department of Physiology & Biophysics, UC Irvine School of Medicine
This study will use tumor samples from patients with Non-Hodgkin lymphoma to generate “organoids,” miniaturized and simplified model systems that can be used to study cancer outside of the human body. We have already demonstrated that we can make organoids from some types of Non-Hodgkin lymphoma and will use these systems to test how well current therapies work for different subtypes of lymphomas. These organoids also provide us with the power to test new therapies, which have the potential to inform treatment strategies on a patient-specific basis.

Active in Vivo Metabolites of p53 Reactivation Small Molecules
Investigators:
Cholsoon Jang, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
Scott Rychnovsky, PhD, Department of Chemistry, UC Irvine School of Physical Sciences
Peter Kaiser, PhD, Department of Biological Chemistry, UC Irvine School of Medicine
This proposal aims to identify active drug-like molecules that restore the body’s own anti-tumor mechanism, the tumor suppressor protein p53, which is the most frequently mutated protein in human cancers. Each year in the U.S., about 600,000 new cancer patients are diagnosed with tumors carrying p53 cancer mutants, which are particularly enriched in aggressive, hard-to-treat tumors. We have analyzed and found drug-like molecules in mouse tumor models that are metabolized to highly active p53 reactivation molecules. In this proposal, we seek to identify the chemical structure of these p53 reactivation molecules to develop drugs that restore p53 activity for novel cancer treatment.